KR101347442B1 - Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone A - Google Patents
Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone A Download PDFInfo
- Publication number
- KR101347442B1 KR101347442B1 KR1020087021465A KR20087021465A KR101347442B1 KR 101347442 B1 KR101347442 B1 KR 101347442B1 KR 1020087021465 A KR1020087021465 A KR 1020087021465A KR 20087021465 A KR20087021465 A KR 20087021465A KR 101347442 B1 KR101347442 B1 KR 101347442B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- agent
- helipyrone
- scavenger
- group
- Prior art date
Links
- BYRZLWJKTOLLBX-UHFFFAOYSA-N Helipyrone Chemical compound CC1=C(CC)OC(=O)C(CC=2C(OC(CC)=C(C)C=2O)=O)=C1O BYRZLWJKTOLLBX-UHFFFAOYSA-N 0.000 title abstract description 62
- 230000003078 antioxidant effect Effects 0.000 title abstract description 14
- 239000003795 chemical substances by application Substances 0.000 title abstract description 14
- 239000003963 antioxidant agent Substances 0.000 title abstract description 12
- 229940123973 Oxygen scavenger Drugs 0.000 title abstract description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title description 73
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 title description 12
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 title description 10
- 230000001153 anti-wrinkle effect Effects 0.000 title description 5
- 239000002516 radical scavenger Substances 0.000 title description 5
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 239000003112 inhibitor Substances 0.000 title description 4
- 238000007665 sagging Methods 0.000 title description 2
- 239000007854 depigmenting agent Substances 0.000 title 1
- 230000037303 wrinkles Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 11
- 230000009759 skin aging Effects 0.000 abstract description 8
- 230000002087 whitening effect Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 4
- 229940088382 Nitric oxide scavenger Drugs 0.000 abstract description 2
- 239000003623 enhancer Substances 0.000 abstract description 2
- 229940124200 Melanin inhibitor Drugs 0.000 abstract 1
- 230000002000 scavenging effect Effects 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 34
- 238000012360 testing method Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- -1 fatty acid esters Chemical class 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000005406 washing Methods 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 14
- 235000013734 beta-carotene Nutrition 0.000 description 14
- 239000011648 beta-carotene Substances 0.000 description 14
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 14
- 229960002747 betacarotene Drugs 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
- 102000003425 Tyrosinase Human genes 0.000 description 13
- 108060008724 Tyrosinase Proteins 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 108091006003 carbonylated proteins Proteins 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- MTIRIKBRVALRPJ-NTMALXAHSA-N (Z)-[3-aminopropyl(propan-2-yl)amino]-hydroxyimino-oxidoazanium Chemical compound CC(C)N(CCCN)[N+](\[O-])=N\O MTIRIKBRVALRPJ-NTMALXAHSA-N 0.000 description 8
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000002224 dissection Methods 0.000 description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000001678 irradiating effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 6
- 229930013799 (-)-catechin Natural products 0.000 description 6
- 235000007331 (-)-catechin Nutrition 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000005713 Keratin-1 Human genes 0.000 description 6
- 108010070514 Keratin-1 Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940043353 maltol Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 102000019040 Nuclear Antigens Human genes 0.000 description 3
- 108010051791 Nuclear Antigens Proteins 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940005654 nitrite ion Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000013319 spin trapping Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VDVUCLWJZJHFAV-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidin-4-ol Chemical compound CC1(C)CC(O)CC(C)(C)N1 VDVUCLWJZJHFAV-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100031784 Loricrin Human genes 0.000 description 2
- 229920000877 Melamine resin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001362 electron spin resonance spectrum Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010079309 loricrin Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- ZIIQCSMRQKCOCT-UHFFFAOYSA-N 2-acetamido-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound CC(=O)NC(C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- ALTHQTNZTJKVKU-UHFFFAOYSA-N 4-prop-1-en-2-ylmorpholine Chemical compound CC(=C)N1CCOCC1 ALTHQTNZTJKVKU-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- IQHOROXWKMJWLO-UHFFFAOYSA-N C(=C)(C)N1CCOCC1.C(=C)(C)N1CCOCC1 Chemical compound C(=C)(C)N1CCOCC1.C(=C)(C)N1CCOCC1 IQHOROXWKMJWLO-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001046961 Mus musculus Keratin, type II cytoskeletal 1 Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ABKDZANKXKCXKG-UHFFFAOYSA-B P(=O)([O-])([O-])[O-].[W+4].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].[W+4].[W+4] Chemical compound P(=O)([O-])([O-])[O-].[W+4].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].[W+4].[W+4] ABKDZANKXKCXKG-UHFFFAOYSA-B 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- IBVJFULICYLKCE-BDVNFPICSA-N methyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]carbamodithioic acid Chemical compound SC(=S)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IBVJFULICYLKCE-BDVNFPICSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- AWXXNBQGZBENFO-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1.C1COCCN1 AWXXNBQGZBENFO-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical class OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pyrane Compounds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 헬리피론 A(Helipyrone A)에 관한 새로운 작용을 발견하여, 그 유효 이용인 헬리피론 A(Helipyrone A)를 함유하는 일중항산소 소거제, 피부노화 개선제, 주름 개선제, 처짐 개선제, 피부수분량 개선제, 미백제, 멜라닌 억제제, 일산화질소 소거제 또는 산화방지제를 제공하는 것을 과제로 한다.The present invention finds a new action on Helipyrone A, the single-use oxygen scavenger, skin aging enhancer, wrinkle improver, sag improver, skin moisture amount containing the effective use of Helipyrone A (Helipyrone A) An object of the present invention is to provide an improving agent, a whitening agent, a melanin inhibitor, a nitric oxide scavenger or an antioxidant.
Description
본 발명은 헬리피론 A(Helipyrone A)에 관한 것이다.The present invention relates to Helipyrone A.
비특허문헌 1(Journal of ethnopharmacology 33(1991) p51-55)에는, 화학식 1로 나타내어지는 헬리피론 A(Helipyrone A)가 항균작용을 갖는 것이 개시되어 있다.Non-Patent Document 1 (Journal of ethnopharmacology 33 (1991) p51-55) discloses that helipyrone A represented by the general formula (1) has an antibacterial effect.
비특허문헌 1: Journal of ethnopharmacology 33(1991) p51-55Non Patent Literature 1: Journal of ethnopharmacology 33 (1991) p51-55
비특허문헌 2: Esahak Ali, et al., Phytochemistry, 1982, 21, 243-244Non-Patent Document 2: Esahak Ali, et al., Phytochemistry, 1982, 21, 243-244
발명의 개시DISCLOSURE OF INVENTION
발명이 해결하고자 하는 과제Problems to be solved by the invention
본 발명의 과제는 헬리피론 A(Helipyrone A)에 관한 새로운 작용을 발견하여, 그 유효 이용을 도모하는 것이다.An object of the present invention is to discover a novel action on Helicyrone A and to promote its effective use.
과제를 해결하기 위한 수단Means for solving the problem
본 발명의 주된 구성은 다음과 같다.The main configuration of the present invention is as follows.
1. 화학식 1로 표시되는 헬리피론 A(Helipyrone A)를 함유하는 일중항산소 소거제, 피부노화 개선제, 주름 개선제, 처짐 개선제, 피부수분량 개선제, 미백제, 멜라닌 억제제, 일산화질소 소거제 또는 산화방지제.1. Singlet oxygen scavengers, skin aging enhancers, wrinkle improvers, sag improvers, skin moisture improvers, whitening agents, melanin inhibitors, nitric oxide scavengers or antioxidants containing Helicyrone A represented by the formula (1).
2. 1.에 기재된 어느 하나의 제(劑)를 함유하는 경구용 조성물.2. An oral composition containing any one of 1.
3. 1.에 기재된 어느 하나의 제를 함유하는 피부외용 조성물.3. The composition for external use of skin containing any one of 1.
4. 1.에 기재된 어느 하나의 제를 함유하는 식품.4. Food containing any one of 1. agent.
5. 1.에 기재된 어느 하나의 제를 함유하는 의약.5. A medicament containing any one of 1.
6. 1.에 기재된 어느 하나의 제를 함유하는 화장료.6. Cosmetics containing any one of 1. agents.
발명의 효과Effects of the Invention
헬리피론 A(Helipyrone A)에 관해, 새로이, 일중항산소 소거, 피부노화 개선, 주름 개선, 처짐 개선, 피부수분량 개선, 미백, 멜라닌 억제, 일산화질소 소거 또는 산화방지의 작용효과를 확인하였다. 이것을 활용한 신규한 각종 제, 의약, 식품, 화장품을 제공할 수 있다.With respect to Helipyrone A, the effects of singlet oxygen scavenging, skin aging, wrinkle improvement, sag improvement, skin moisture content improvement, whitening, melanin inhibition, nitric oxide scavenging or anti-oxidation were confirmed. Various novel agents, medicines, foods, and cosmetics utilizing this can be provided.
도 1은 주름 스코어를 나타내는 그래프이다.1 is a graph showing wrinkle score.
도 2는 피부수분량을 나타내는 그래프이다.2 is a graph showing skin moisture content.
도 3은 피부 경도(硬度)를 나타내는 그래프이다.3 is a graph showing skin hardness.
도 4는 카르보닐화 단백질량(상대값)을 나타내는 그래프이다.4 is a graph showing the amount of carbonylated protein (relative value).
도 5는 피부조직 중 8-히드록시 2'-데옥시구아노신(8-hydroxy 2'-deoxy guanosine)량(상대값)을 나타내는 그래프이다.5 is a graph showing the amount (relative value) of 8-hydroxy 2'-deoxy guanosine in skin tissue.
도 6은 피부조직 중 과산화지질량을 나타내는 그래프이다.6 is a graph showing the mass of peroxide in skin tissue.
도 7은 ESR법에 의한 일산화질소 소거능을 나타내는 그래프이다.7 is a graph showing nitrogen monoxide scavenging ability by the ESR method.
도 8은 비색법(Griess법)에 의한 일산화질소 소거능을 나타내는 그래프이다.8 is a graph showing nitrogen monoxide scavenging ability by the colorimetric method (Griess method).
도 9는 비색법에 의한 과산화아질산염(peroxynitrite) 소거능을 나타내는 그래프이다.9 is a graph showing the peroxynitrite scavenging ability by the colorimetric method.
도 10은 증식세포 핵 항원(Proliferation Cell Nuclear Antigen, PCNA) 증가 억제능을 나타내는 그래프이다.10 is a graph showing the inhibitory ability to increase Proliferation Cell Nuclear Antigen (PCNA).
도 11은 로리크린(loricrin) 억제능을 나타내는 그래프이다.11 is a graph showing the loricrin inhibitory ability.
도 12는 케라틴 1 억제능을 나타내는 그래프이다.12 is a
발명을 실시하기Carrying out the invention 위한 최선의 형태 Best form for
헬리피론 A(Helipyrone A)는 다음 화학식 1로 표시된다.Helipyrone A is represented by the following formula (1).
[화학식 1][Formula 1]
이 헬리피론 A(Helipyrone A)에는 주름 억제효과, 피부노화 개선, 광노화, 미백, 멜라닌 생성 억제, 항산화, 일중항산소 소거, 일산화질소 소거 등의 신규한 작용이 있는 것을 알게되었다. 이들 신규한 지견(知見)을 토대로, 화장료 조성물, 식품 첨가 소재, 의약 소재로서 이용할 수 있다.Helipyrone A has been found to have novel effects such as anti-wrinkle effect, skin aging improvement, photo aging, whitening, melanin production inhibition, antioxidant, singlet oxygen scavenging and nitric oxide scavenging. Based on these novel knowledge, it can use as a cosmetic composition, a food addition material, and a pharmaceutical material.
화장료, 식품으로서는 주름 억제효과, 피부노화 개선, 광노화, 미백, 멜라닌 생성 억제, 항산화, 일중항산소 소거를 기대할 수 있어, 피부노화 개선제, 광노화 억제제, 미백제, 멜라닌 생성 억제제, 항산화제, 일중항산소 소거제, 일산화질소 소거제로서 사용할 수 있다.As cosmetics and foods, anti-wrinkle effect, skin aging improvement, photo aging, whitening, melanin production inhibition, antioxidant, singlet oxygen scavenging can be expected, skin aging improving agent, photoaging inhibitor, whitening agent, melanin production inhibitor, antioxidant, singlet oxygen It can be used as a scavenger and a nitrogen monoxide scavenger.
본 발명의 헬리피론 A(Helipyrone A)를 함유하는 화장료(의약부외품을 포함하는)로서는, 얼굴용 또는 손, 발, 바디용 보습 화장료로서 로션, 유액, 크림, 젤, 다층형 화장료 등을 들 수 있다. 또한 립스틱, 파운데이션 등의 메이크업 화장료, 세안료, 핸드 클리너, 바디샴푸 등의 세정제, 샴푸, 린스, 트리트먼트, 육모제 등의 모발용 화장료로서 사용하는 것도 가능하다.Examples of the cosmetics (including quasi-drugs) containing helipyrone A of the present invention include moisturizing cosmetics for face or hands, feet and body, such as lotions, emulsions, creams, gels, and multilayer cosmetics. have. Moreover, it can also be used as hair cosmetics, such as makeup cosmetics, such as a lipstick and a foundation, washing | cleaning agents, such as a face wash, a hand cleaner, and a body shampoo, a shampoo, a rinse, a treatment, and a hair growth agent.
본 발명의 헬리피론 A(Helipyrone A)를 함유하는 화장료(의약부외품을 포함하는)로는, 헬리피론 A(Helipyrone A) 이외에, 화장료 조성물로서 일반적으로 사용되고 있는 소재를 사용할 수 있다. 예를 들면 탄화수소유, 에스테르유, 지방산, 고 급 알코올, 실리콘, 스테롤, 세라미드 등의 유제(油劑), 다가 알코올, 당, 피롤리돈 카르복실산, 아미노산, 베타인 등의 보습제, 비이온 계면활성제, 음이온 계면활성제, 양이온 계면활성제, 양성 계면활성제, 반극성 계면활성제, 레시틴 등의 계면활성제, 고분자 유화제, 수용성 고분자, 팔미트산 덱스트린 등의 증점제, 무기 분체, 유기 분제, 항균제, 살균제, pH 조정제, 킬레이트제, 착색제, 향료, 식물 추출물 등을 배합할 수 있다.As the cosmetics (including quasi-drugs) containing helipyrone A of the present invention, a material generally used as a cosmetic composition can be used in addition to helipyrone A. For example, hydrocarbon oils, ester oils, fatty acids, higher alcohols, emulsions such as silicones, sterols, ceramides, polyhydric alcohols, sugars, humectants such as pyrrolidone carboxylic acids, amino acids, betaines, and nonionics Surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, surfactants such as semipolar surfactants, lecithin, polymer emulsifiers, water-soluble polymers, thickeners such as dextrin palmitate, inorganic powders, organic powders, antibacterial agents, bactericides, A pH adjuster, a chelating agent, a coloring agent, a fragrance, a plant extract, etc. can be mix | blended.
본 발명의 헬리피론 A(Helipyrone A)를 함유하는 식품으로서는, 헬리피론 A(Helipyrone A)를 그대로, 또는 각종 영양성분을 첨가하여 식품으로서 사용할 수 있고, 목적하는 식품에 배합해도 된다. 예를 들면 전분, 젖당, 맥아당, 식물유지 분말, 카카오버터 분말, 스테아르산 등의 적당한 보조제를 첨가한 후, 관용의 수단을 사용하여, 식용에 적합한 형태, 예를 들면 과립상, 입상, 정제, 캡슐, 페이스트 등으로 성형하여 건강식품, 보건기능식품 등으로 할 수 있다. 또한 각종 식품, 예를 들면 햄, 소세지 등의 식육가공식품, 어묵, 꼬치어묵 등의 수산가공식품, 빵, 과자, 버터, 분유, 발효유제품에 첨가해도 되고, 물, 과즙, 우유, 청량음료 등의 음료에 첨가하여 사용해도 된다.As food containing Helicyrone A of this invention, Helicyrone A can be used as a food as it is, or various nutrients can be added, and you may mix | blend with the food of interest. For example, starch, lactose, maltose, plant oil powder, cacao butter powder, stearic acid and the like are added, and then, by using conventional means, a form suitable for edible food such as granular, granular, tablet, It can be molded into capsules, pastes, etc. to form health foods, health functional foods, and the like. It may be added to various foods, for example, meat processed foods such as ham and sausage, fish processed foods such as fish paste and skewered fish paste, bread, confectionery, butter, powdered milk and fermented milk products, and water, fruit juice, milk and soft drinks. You may use it in addition to drink.
본 발명의 헬리피론 A(Helipyrone A)를 함유하는 의약으로서는 경구투여, 경피투여, 직장내 투여, 주사 등의 투여방법에 적합한 고체 또는 액체의 의약용 무독성 담체(擔體)와 혼합하여, 관용의 의약제제의 형태로 투여할 수 있다.As a medicament containing Helipyrone A of the present invention, it is mixed with a solid or liquid pharmaceutical non-toxic carrier suitable for administration methods such as oral administration, transdermal administration, rectal administration, injection, and the like. It may be administered in the form of a pharmaceutical preparation.
이와 같은 제제로서는, 예를 들면 정제, 과립제, 산제, 캡슐제 등의 고형제, 용액제, 현탁제, 유제 등의 액제, 동결건조제제 등을 들 수 있고, 이들 제제는 제 제상의 상투 수단에 의해 조제할 수 있다.Such preparations include, for example, solid preparations such as tablets, granules, powders and capsules, liquid preparations such as solutions, suspensions and emulsions, lyophilized preparations, and the like. It can be prepared by.
상기 의약용 무독성 담체로서는, 예를 들면 글루코오스, 젖당, 자당, 전분, 만니톨, 덱스트린, 지방산 글리세리드, 폴리에틸렌글리콜, 히드록시에틸 전분, 에틸렌글리콜, 폴리옥시에틸렌소르비탄 지방산에스테르, 아미노산, 젤라틴, 알부민, 물, 생리식염수 등을 들 수 있다. 또한, 필요에 따라서 안정화제, 습윤제, 유화제, 결합제, 등장화제 등 관용의 첨가제를 적절히 첨가하는 것도 가능하다.Examples of the non-toxic carrier for medical use include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glycerides, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid esters, amino acids, gelatin, albumin, Water, physiological saline, and the like. Moreover, it is also possible to add conventional additives suitably, such as a stabilizer, a wetting agent, an emulsifier, a binder, and an isotonic agent as needed.
[헬리피론 A(Helipyrone A)의 화학 합성][Chemical Synthesis of Helipyrone A]
헬리피론 A(Helipyrone A)의 화학 합성에 대해서는, 비특허문헌 2(Esahak Ali, et al., Phytochemistry, 1982, 21, 243-244)에 개시되어 있다.The chemical synthesis of Helipyrone A is disclosed in Non Patent Literature 2 (Esahak Ali, et al., Phytochemistry, 1982, 21, 243-244).
예를 들면, 본 발명에서는 다음과 같이 합성하였다.For example, in this invention, it synthesize | combined as follows.
400 mL의 헥산 용매를 사용하여, 사염화티탄의 존재하에서 화합물 1 디에틸케톤(3-pentanone) 172 g과 화합물 2 테트라히드로-1,4-옥사진(tetrahydro-1,4-oxazine(morpholine)) 1,000 g을 4℃에서 3시간 반응시키고, 증류 처리로 정제하여, 화합물 3 (N-이소프로페닐)-테트라히드로-1,4-옥사진((N-isopropenyl)-tetrahydro-1,4-oxazine) 503.57 g(수율 81.1%)을 얻었다.172 g of
200 mL의 톨루엔 용매를 사용하여, 화합물 3 (N-이소프로페닐)-테트라히드로-1,4-옥사진((N-isopropenyl)-tetrahydro-1,4-oxazine) 167 g을 화합물 4 에틸 말로닐 클로라이드(ethyl malonyl chloride) 81 g과 메탄올-빙냉(-17℃~-11℃) 조건에서 반응시켜, 화학식 2로 표시되는 화합물 5를 합성하였다.Using 200 mL of toluene solvent, 167 g of Compound 3 (N-isopropenyl) -tetrahydro-1,4-oxazine was added to
화합물 3과 화합물 4의 반응은 2 N 염산 첨가로 종료시키고, 클로로포름 추출 후에 황산마그네슘 건조 처리를 행하였다. 그 다음으로 반응용액에 톨루엔 200 mL와 25% 염산 400 mL를 순차 첨가하여 액-액 분배로 톨루엔층을 회수하였다. 톨루엔층을 0.1 N 염산 400 mL로 세정하고, 황산마그네슘 건조 처리 후에 톨루엔을 진공 증발기로 제거하여 오렌지색 유상(油狀) 용액을 얻었다. 이 용액에 PPA(폴리인산) 1 ㎏을 첨가하고, 110℃~118℃에서 환화(環化)하여 화합물 5를 합성하였다. 화합물 5는 실온으로 냉각하고, 클로로포름 추출로 회수하여, 황산마그네슘 건조 처리 후에 진공 증발기로 클로로포름을 제거하였다. 고형물을 실리카겔크로마토그래피(클로로포름:메탄올=50:1(v/v))로 오렌지색 고형의 화합물 5를 45.7 g 얻었다. 본 반응의 수율은 18.3%였다.Reaction of
이 화합물 5에 대해서 1 N 염산 존재하에서 포름알데히드를 중합반응함으로써 화합물 6 헬리피론 A(Helipyrone A)를 화학 합성하였다. 화합물 5의 45.7 g을 에탄올 460 mL에 용해하고, 농염산 2.5 mL의 존재하에서 포름알데히드(37%) 247.81 g을 79℃에서 환류 반응시켜, 결정이 석출되었다. 이 결정을 에탄올 300 mL로 세정하여, 백색 결정으로서 헬리피론 A(Helipyrone A)를 34.01 g 얻었다. 본 반응의 수율은 71.6%였다.
얻어진 헬리피론 A(Helipyrone A)의 물성값을 이하에 나타낸다.The physical-property value of the obtained helipyrone A is shown below.
외관: 백색 결정Appearance: White Crystal
NMR 스펙트럼(400 ㎒, 용매; CDCl3)NMR spectrum (400 MHz, solvent; CDCl 3 )
분자량: 320.341 g/㏖(질량분석)Molecular weight: 320.341 g / mol (mass spectrometry)
분자식: C17H20O6(질량분석)Molecular Formula: C 17 H 20 O 6 (Mass Spectrometry)
융점: 218-220℃Melting Point: 218-220 ℃
[항산화능 평가]Antioxidant Evaluation
헬리피론 A(Helipyrone A)에 대해서, 일중항산소 소거작용의 평가를 행하였다. 평가법은 2,2,6,6-테트라메틸-4-피페리디놀(2,2,6,6-tetramethyl-4- piperidinol(4-OH TEMP))을 스핀트랩제로 한 ESR 스핀트랩법에 의해 측정하였다. 먼저, 시판의 바닥이 평평한 96 웰 마이크로플레이트에 임의의 농도로 조제한 헬리피론 A(Helipyrone A)의 40%(v/v) N,N-디메틸포름아미드 수용액 0.1 mL를 첨가하고, 계속해서 증류수 0.02 mL를 첨가하고, 100 mM의 4-OH TEMP 수용액 0.04 mL, 0.1 mM의 로즈 벵갈(rose bengal) 수용액 0.04 mL와 혼합하여, 0.2 mL의 혼합액으로 하였다. 이것에 광증감 반응의 광원으로서 마이크로플레이트의 배면(背面)으로부터 극대 파장 530 ㎚의 발광 다이오드(녹색 LED)를 20분간 조사하여 일중항산소를 발생시켰다. 이 혼합액을 ESR용 편평 수용액 셀로 옮겨, ESR 스펙트럼을 측정하였다. ESR 스펙트럼 강도로부터 일중항산소 소거율을 구하고, 이것을 농도에 대해 플롯하여, 50% 억제 농도 IC50값을 구하였다. 또한, 비교로서, 기존의 폴리페놀 화합물(실리빈, 3,4-디히드록시페닐에탄올, (-)-카테킨, (-)-에피카테킨 갈레이트, 케르세틴(Quercetin), 로즈마린산, 카르노신산(carnosic acid), 카페산(caffeic acid), 코지산(kojic acid), β-카로틴)의 IC50값을 동시에 구하였다. 그 결과를 표 1에 나타낸다.Helipyrone A was evaluated for singlet oxygen scavenging action. The evaluation method was performed by the ESR spin trapping method using 2,2,6,6-tetramethyl-4-piperidinol (2,2,6,6-tetramethyl-4-piperidinol (4-OH TEMP)) as a spin trapping agent. Measured. First, 0.1 mL of 40% (v / v) N, N-dimethylformamide solution of Helicyrone A prepared at an arbitrary concentration was added to a 96-well microplate having a flat bottom, and then distilled water 0.02 mL was added and mixed with 0.04 mL of 100 mM 4-OH TEMP aqueous solution and 0.04 mL of 0.1 mM rose bengal aqueous solution to prepare a mixed solution of 0.2 mL. As a light-sensitizing light source, a single-light oxygen was generated by irradiating a light emitting diode (green LED) having a maximum wavelength of 530 nm for 20 minutes from the back of the microplate. This mixed solution was transferred to the flat aqueous solution cell for ESR, and the ESR spectrum was measured. The singlet oxygen scavenging ratio was determined from the ESR spectral intensity, and plotted against the concentration to obtain a 50% inhibition concentration IC50 value. In addition, as a comparison, conventional polyphenol compounds (silbin, 3,4-dihydroxyphenylethanol, (-)-catechin, (-)-epicatechin gallate, quercetin, rosemarine acid, carnosic acid ), Caffeic acid, kojic acid, and β-carotene) were obtained at the same time. The results are shown in Table 1.
이 결과로부터 명확하듯이, 다른 폴리페놀 화합물과 비교해서, 헬리피론 A(Helipyrone A)는 보다 저농도에서 일중항산소를 소거하는 것이 인정되었다. 즉, 헬리피론 A(Helipyrone A)는 우수한 일중항산소 소거작용을 나타내는 것이 명확해졌다.As is clear from these results, it was recognized that helipyrone A eliminated singlet oxygen at lower concentrations compared to other polyphenol compounds. In other words, it was clear that Helipyrone A showed excellent singlet oxygen scavenging action.
[멜라닌 생성 억제 시험][Melanin Production Inhibition Test]
시판의 6 웰 플레이트에 각각 마우스 B16 흑색종 세포를 5% CO2, 37℃의 조건하에서 배양액 10% FBS(소 태아 혈청)를 포함하는 DMEM을 사용하여 컨플루언트까지 배양하였다. 멜라닌 생성 자극제인 100 nM αMSH를 첨가하고, 동시에 0.0001%의 헬리피론 A를 첨가하여 72시간 계속해서 배양하였다. 용매조건은 10% FBS 함유 DMEM 배지이나, 헬리피론 A의 용해도를 고려하여, 0.2% 아세토니트릴를 모든 웰에 함유시켰다. 배양 종료 후, 세포 분획을 회수하고, 0.1 N NaOH 알칼리 처리로 멜라닌 색소를 용해시켜, 405 ㎚의 흡광도(ABS)를 측정하였다.Commercially available 6-well plates of mouse B16 melanoma cells were each incubated to confluent using DMEM containing 10% FBS (fetal bovine serum) in culture under conditions of 5% CO 2 , 37 ° C. 100 nM αMSH as a melanogenesis stimulator was added, followed by incubation for 72 hours with the addition of 0.0001% of helipyron A. Solvent conditions were 10% FBS containing DMEM medium, 0.2% acetonitrile was contained in all wells in consideration of the solubility of helipyrone A. After completion of the culture, the cell fractions were collected, the melanin pigment was dissolved by 0.1 N NaOH alkali treatment, and the absorbance (ABS) at 405 nm was measured.
멜라민 생성 억제율을Melamine production inhibition
멜라민 생성 억제율[%]=100×{1-(ABS[Sample])/(ABS[Control])}Melamine production inhibition rate [%] = 100 × {1- (ABS [Sample]) / (ABS [Control])}
Control: 0.2% 아세토니트릴 함유 DMEM 배지Control: DMEM medium containing 0.2% acetonitrile
Sample: 0.2% 아세토니트릴 함유 0.0001% 헬리피론 A 첨가(DMEM 배지)Sample: 0.201% acetonitrile containing 0.0001% helipyrone A (DMEM medium)
의 식으로 산출하였다..
그 결과, 헬리피론 A를 0.0001% 첨가하였을 때는 22.1%±8.4(S.D.) 멜라닌 생성이 억제되었다.As a result, 22.1% ± 8.4 (S.D.) melanin production was inhibited when 0.0001% of helipyron A was added.
[자외선 조사에 의한 주름 억제 시험][Wrinkle suppression test by ultraviolet irradiation]
미약한 자외선을 장기간 계속 조사함으로써 피부노화의 현상인 주름·처짐을 형성시킨 누드 마우스(hairless mouse)를 동물 모델로서 실시하고, 이때 헬리피론 A를 사료와 혼합하여 투여하였을 때의 영향을 해석하였다.Nude mice (hairless mice) that form wrinkles and sags, which are a phenomenon of skin aging by continuously irradiating weak ultraviolet rays for a long time, were conducted as animal models, and the effects of the administration of helipyrone A in combination with feed were analyzed.
I. 실험동물I. Experimental Animal
·종·계통·성별Species, line, sex
종: 마우스, 계통: Hos:HR1(누드 마우스), 성별: 암컷Species: Mice, Line: Hos: HR1 (nude mouse), Gender: Female
·사육 개시주령Age of breeding start
5주령부터 사육, 동시에 사료와 혼합하여 투여하기를 개시하였다.Breeding from 5 weeks of age, at the same time mixed with the feed was started to administer.
II. 사육환경II. Breeding environment
설정 온습도: 24±1℃, 상대습도 55±5%Set temperature and humidity: 24 ± 1 ℃, relative humidity 55 ± 5%
공기조절설비: 올후레쉬 방식Air Conditioning Equipment: All Fresh
조명시간: 12시간 자동 점등·소등 방식Illumination time: 12 hours auto on / off
사육설비: 플라스틱제 케이지 5마리/케이지Breeding equipment: 5 plastic cages / cage
사료: 분말 멸균사료 MF-1(오리엔탈 효모공업(주))을 자유 섭취, 또는 MF-1에 헬리피론 A를 각각 0.01%(w/w), 0.05%(w/w), 0.1%(w/w) 또는 항산화효과가 우수한 β 카로틴을 0.01%(w/w), 0.05%(w/w) 혼합하였다.Feed: Free intake of powdered sterilized feed MF-1 (Oriental Yeast Industry Co., Ltd.) or 0.01% (w / w), 0.05% (w / w), 0.1% (w) of helipyron A in MF-1, respectively. / w) or β-carotene with excellent antioxidant effect was mixed 0.01% (w / w), 0.05% (w / w).
III. 시험 스케줄III. Exam Schedule
자외선 조사조건: 격일(하루 간격)로 10주간, 자외선 램프를 사용하여, UV-A파 14 J/㎠(조사시간 약 1분), UV-B파 20 mJ/㎠(조사시간 약 50분)를 구속 스트레스를 가하지 않고 조사하였다. 10주간(35회)의 전 조사량은 UV-A파 490 J/㎠, UV-B파 700 mJ/㎠이다.UV irradiation conditions: UV-A wave 14 J / cm 2 (irradiation time about 1 minute), UV-
자외선 조사를 계속한 군에 대해서는 해부 24시간 전에 마지막 자외선 조사를 실시하였다. 해부 18시간 전부터 절식을 행하였다. 해부 전에 비침습적 수법에 의해 피부수분량을 간이 수분계(Moisture CheckerTM, 스칼라제)를 사용하여 측정하였다.In the group which continued ultraviolet irradiation, the last ultraviolet irradiation was performed 24 hours before dissection. Fasting was performed 18 hours before dissection. The skin moisture content was measured using a simple moisture meter (Moisture Checker ™ , scalase) by a non-invasive method before dissection.
넴부탈 마취를 행하고, 외관을 사진 촬영하였다. 그리고 피부 배부(背部)의 레플리카를 채취하였다.Nembutal anesthesia was performed and the appearance was photographed. And a replica of skin distribution was taken.
해부에 의해, 간장 적출, 전혈 회수, 배부 및 복부의 피부를 회수하였다.By dissection, hepatic extraction, whole blood recovery, backing, and abdominal skin were recovered.
장기는 신속히 동결 보존하고, 전혈은 원심분리(3,000 G, 20 min, 실온)를 행하여 혈장(plasma)을 회수하고 냉동 보존하였다. 피부는 배부의 일정 면적을 부앙(Bouin) 고정하여 조직 염색용으로 사용한 것 외에는 냉동 보존하였다.Organs were rapidly cryopreserved and whole blood was centrifuged (3,000 G, 20 min, room temperature) to recover plasma and cryopreserved. The skin was cryopreserved except that it fixed a certain area of the belly and was used for tissue staining.
외관상의 피부상태를 경부(頸部)의 처짐(Sagging), 배부의 주름(Wrinkle)의 형성 상황에 착안하여 Bissett DL 등의 정의(Photochem Photobiol.(1987) Vol.46, No.3, pp367-pp378)에 따라 스코어화하였다. 즉, 하기에 나타내는 정의에 따라 수치화하고, 판단이 곤란한 검체는 중간값으로서 0.5를 붙였다. 주름 스코어의 데이터를 그래프화하여 도 1에 나타낸다.The appearance of Bissett DL et al. (Photochem Photobiol. (1987) Vol.46, No.3, pp367-), focusing on the appearance of the sagging of the neck and the formation of wrinkles on the back. pp378). That is, it quantified according to the definition shown below, and the sample which was difficult to judge added 0.5 as an intermediate value. The data of the wrinkle score is graphed and shown in FIG. 1.
·스코어 0
주름의 발생이 전혀 인정되지 않는다.The occurrence of wrinkles is not recognized at all.
정지상태에서 척추방향에 대해 수직인 선이 인정되지 않거나, 약간 인정되는 정도, 그리고 개체의 운동에 따라 그 선은 소실된다.In a stationary state, the line perpendicular to the spine direction is not recognized, or slightly accepted, and depending on the individual's movement, the line is lost.
·스코어 1
경미한 주름의 발생이 명확하게 인정된다.The occurrence of minor wrinkles is clearly recognized.
척추방향에 대해 수직인 선이 인정되고, 개체의 운동에 따라 그 선은 소실된다.A line perpendicular to the spine direction is recognized, and the line is lost as the individual moves.
·스코어 2
중간 정도의 주름의 발생이 명확하게 인정된다.The occurrence of moderate wrinkles is clearly recognized.
척추방향에 대해 명확하게 선이 인정되고, 개체의 운동에 따라 그 선은 소실되지 않고 영속적이다.The line is clearly recognized for the direction of the spine, and as the individual moves, the line is not lost and is permanent.
·스코어 3
깊은 주름의 발생이 명확하게 인정된다.The occurrence of deep wrinkles is clearly recognized.
척추방향에 대해 명확하게 선이 인정되고, 그 선에 대해 그림자가 인정되며, 개체의 운동에 따라 그 선은 소실되지 않고 영속적이다.The line is clearly recognized for the direction of the spine, the shadow is recognized for the line, and according to the individual's movement, the line is not lost and is permanent.
주름 스코어는 자외선 조사 10주간의 MF-1(대조)식군 2.4인 것에 비해, 자외선 조사 10주간의 헬리피론 A를 0.1% 배합한 MF-1식군 0.1, 자외선 조사 10주간의 헬리피론 A를 0.05% 배합한 MF-1식군 0.2, 자외선 조사 10주간의 헬리피론 A를 0.01% 배합한 MF-1식군 0.6으로서, 주름의 생성이 현저히 억제되었다. 자외선을 조사하지 않고 10주간 경과한 MF-1(대조)식군의 주름 스코어는 0.2로서, 헬리피론 A의 0.05~0.1% 배합식을 섭취함으로써 자외선 조사에 의한 주름의 발생이 완전히 억제되고 있다.Wrinkle score was 0.05% of MF-1 group 0.1 which blended 0.1% of helipyron A for 10 weeks of ultraviolet irradiation, helipyron A for 10 weeks of ultraviolet irradiation compared with that of MF-1 (control) group 2.4 for 10 weeks of ultraviolet irradiation. Formation of wrinkles was remarkably suppressed as MF-1 type | group group 0.6 which mix | blended 0.01% of MF-1 type | formula which was mix | blended and 0.01% of helipyron A for 10 weeks of ultraviolet irradiation. The wrinkle score of the MF-1 (control) diet group which elapsed for 10 weeks without irradiating an ultraviolet-ray was 0.2, and generation | occurrence | production of the wrinkle by ultraviolet irradiation is suppressed completely by ingesting 0.05-0.1% of compound formula of helipyron A.
피부 소견의 결과로부터, 헬리피론 A의 현저한 주름 억제효과가 인정된다. 헬리피론 A의 마우스로의 투여는, 마우스 1일 섭식량 4 g, 채표면적 환산식 y=(3√x)2를 이용하여 인간으로의 투여량으로 환산하면 0.1%의 혼합사료 자유섭취로 약 520 ㎎/일/60 ㎏ 체중, 0.01%의 혼합사료 자유섭취로 약 52 ㎎/일/60 ㎏ 체중에 상당하여, 식품으로서 무리 없이 섭취하는 것이 가능한 양이다.From the results of the skin findings, remarkable anti-wrinkle effect of helipyrone A is recognized. The administration of helipyrone A to the mouse is about 520 with a free feed of 0.1% of the daily dose of human, using 4 g of the daily dose of the mouse and the surface area equation y = (3√x) 2. It is an amount equivalent to about 52 mg / day / 60 kg body weight with a mg / day / 60 kg body weight and 0.01% free of mixed feed, so that it can be easily consumed as food.
또한, 항산화작용을 갖는 β-카로틴 섭식군은 주름 억제효과를 나타내지 않았다.In addition, the β-carotene feeding group having antioxidant activity did not show an anti-wrinkle effect.
자외선 조사 10주간의 β-카로틴을 0.05% 배합한 MF-1식군의 주름 스코어는 2.0, 자외선 조사 10주간의 β-카로틴을 0.01% 배합한 MF-1식군 주름 스코어는 2.3이었다.The wrinkle score of the MF-1 diet group which contained 0.05% of β-carotene for 10 weeks of ultraviolet irradiation was 2.0, and the MF-1 group group wrinkle score which contained 0.01% of β-carotene for 10 weeks of ultraviolet irradiation was 2.3.
[자외선 조사에 수반하는 피부 건조의 억제][Inhibition of Skin Drying with UV Irradiation]
해부 직전에 비침습적 수법으로 피부수분량을 간이 수분계(Moisture CheckerTM, 스칼라제)를 사용하여 측정하고, 한마리당 5회 측정한 평균 측정값에 대해서 각 군으로 비교하였다. 피부수분량의 측정결과를 도 2에 나타낸다.Immediately before dissection, the skin moisture content was measured using a non-invasive method using a Moisture Checker ™ (scalase), and compared with each group for the average measured value measured five times per animal. The measurement result of skin moisture content is shown in FIG.
자외선 조사 10주간+MF-1(대조)식군에서는 피부수분량이 저하하여 건조상태(피부수분량 31.4%)가 되어있는 것에 비해, 자외선 조사 10주간+헬리피론 A 배합의 MF-1식군에서는 헬리피론 A 0.1% 배합에서 피부수분량 41.3%, 0.05% 배합에서 피부수분량 40.2%, 0.01% 배합에서 피부수분량 38.2%로서, 40% 전후로 유의하게 높은 피부수분량을 보유·유지하고 있었다. 헬리피론 A 배합식군의 피부수분량은, 자외선을 조사하지 않고 10주간 경과한 MF-1(대조)식군의 피부수분량 35.5%보다도 높은 값을 나타내었다.In the MF-1 group of the 10-week UV irradiation + Helicyrone A combination, the skin moisture content decreased in the MF-1 (control) diet group for 10 weeks of ultraviolet irradiation and became dry (skin content 31.4%). The skin moisture content was 41.3% in the 0.1% blend, the skin moisture content was 40.2% in the 0.05% blend, and 38.2% in the 0.01% blend. The skin moisture was maintained around 40%. The skin moisture content of the helipyrone A formula group was higher than the skin moisture content of 35.5% of the MF-1 (control) diet group which had elapsed for 10 weeks without irradiating ultraviolet rays.
[자외선 조사에 수반하는 피부 경화의 억제][Inhibition of Skin Curing with UV Irradiation]
스프링식 경도계(JIS C형) 피부 점탄성 측정장치(Vesmeter: E-100S/웨이브 사이버제)를 사용하여, 배부의 꼬리부착 부분으로부터 머리를 향해 2 ㎝, 요추로부터 우측으로 0.5 ㎝ 부위를 3회 측정하여 경도의 평균을 구하였다. 피부 경도의 측정결과를 도 3에 나타낸다.Using a spring hardness tester (JIS Type C) skin viscoelasticity measuring device (Vesmeter: E-100S / Wave Cyber), measure the
피부 점탄성의 지표로서 알려진 경도는, 그 수치가 높을수록 피부노화가 진행되어 피부의 탄력성이 저하하고 있는 것이 일반적으로 알려져 있다.It is generally known that the hardness known as an indicator of skin viscoelasticity is that skin aging progresses and the elasticity of the skin decreases as the numerical value is higher.
자외선 조사 10주간+MF-1(대조)식군에서는 피부 경화가 현저(도수 15.4)해진 것에 비해, 자외선 조사 10주간+헬리피론 A 배합의 MF-1식군에서는 헬리피론 A 0.1% 배합에서 경도의 도수 8.1, 0.05% 배합에서 경도의 도수 9.1, 0.01% 배합에서 경도의 도수 9.1로서, 자외선을 조사하지 않고 10주간 경과한 MF-1(대조)식군의 경도의 도수 7.2에 비해 약간 경화가 진행되는 정도로 경화가 억제되었다.In the MF-1 type group of UV irradiation for 10 weeks + Helicyron A combination for 10 weeks of ultraviolet irradiation + MF-1 (control) diet group, the hardness of the hardness in 0.1% formulation of helipyron A 8.1, 0.05% blending hardness of 9.1, 0.01% blending hardness of 9.1, the degree to which the curing proceeds slightly compared to the hardness of 7.2 of the MF-1 (control) formula that elapsed for 10 weeks without irradiating ultraviolet rays. Curing was suppressed.
[자외선 조사에 수반하는 피부조직 중 카르보닐화 단백질 생성의 억제][Inhibition of Carbonylated Protein Production in Skin Tissue with UV Irradiation]
산화 단백질 중 하나인 카르보닐화 단백질은 OxyblotTM(CHEMICON사)을 사용하여 평가하였다. 구체적인 방법은 이하와 같다. 마우스 피부를 습중량 약 200 ㎎ 칭량하고, 4℃에서 단백질분해효소 억제제 칵테일(Protease inhibitor cocktail)을 포함하는 Lysis buffer(pH=7.4) 0.2 ㎖를 첨가하여 호모지나이즈하여, 12,000×20분간 원심하고, 그 상청을 필터 여과한 것을 사용하여, 단백 농도를 브래드포드(Bradford)의 방법에 따라 측정하였다. 각각의 단백 시료 20 ㎍에 대해서 카르보닐기를 DNPH화하였다. 단백질을 SDS-PAGE에 의해 분리하고, 단백질 전사장치를 사용하여 PVDF막에 전사하였다. 전사 후의 막은 상온하 30분간 5% 스킴밀크를 포함하는 PBS(-) 용액 중에서 블로킹하고, 스킴밀크를 PBS(-)로 세정 후, 항 DNPH 항체와 4℃에서 하룻밤 반응시키고, 세정 후, 비오틴화 항 마우스 IgG와 1시간 반응시켰다. 세정 후, 형광 검출 키트(ECL PLUS)를 사용하여 PVDF막을 감광하고, 의료용 자동현상장치로 화상을 전사하였다. 결과를 도 4에 나타낸다.Carbonylated protein, one of the oxidized proteins, was evaluated using Oxyblot ™ (CHEMICON). The concrete method is as follows. The skin of the mouse was weighed about 200 mg, homogenized by adding 0.2 ml of Lysis buffer (pH = 7.4) containing a Protease inhibitor cocktail at 4 ° C., and centrifuged for 12,000 × 20 minutes. The protein concentration was measured according to the method of Bradford using the filter which filtered the supernatant. The carbonyl group was DNPH for 20 μg of each protein sample. Proteins were separated by SDS-PAGE and transferred to PVDF membrane using a protein transcription device. The membrane after transcription is blocked in a PBS (-) solution containing 5% skim milk for 30 minutes at room temperature, and the skim milk is washed with PBS (-), and then reacted with anti-DNPH antibody at 4 ° C overnight, followed by biotinylation. It was reacted with anti mouse IgG for 1 hour. After washing, the PVDF film was exposed using a fluorescence detection kit (ECL PLUS), and the image was transferred to a medical automatic developing device. The results are shown in FIG.
그 결과, 자외선 조사 10주간+MF-1(대조)식군에서는 카르보닐화 단백질량의 상대값은 259.4인 것에 대해서, 자외선 조사 10주간+헬리피론 A 배합의 MF-1식군에서는 헬리피론 A 0.1% 배합에서 카르보닐화 단백질량의 상대값은 25.3, 0.05% 배합에서 카르보닐화 단백질량의 상대값은 35.6, 0.01% 배합에서 카르보닐화 단백질량의 상대값은 57.7로서, 카르보닐화 단백질의 생성이 1/10~1/5로 억제되었다. 자외선을 조사하지 않고 10주간 경과한 MF-1(대조)식군의 카르보닐화 단백질량의 상대값은 23.7이고, 헬리피론 A 0.1% 배합식군의 카르보닐화 단백질량의 상대값은 25.7로 동일 정도였다. 따라서, 헬리피론 A는 자외선 조사에 수반하는 카르보닐화 단백질의 생성을 현저히 억제하고 있다.As a result, the relative value of the amount of carbonylated protein in the 10-week UV irradiation + MF-1 (control) diet group is 259.4, while 0.1% of helipyron A in the MF-1 diet group of the 10-hour UV irradiation + Helicyrone A combination The relative value of the amount of carbonylated protein in the formulation was 25.3, the relative value of the amount of carbonylated protein in the 0.05% formulation was 35.6, and the relative value of the amount of carbonylated protein in the 0.01% formulation was 57.7. This was suppressed to 1/10-1/5. The relative value of the carbonylated protein content of the MF-1 (control) diet group after 2 weeks without irradiating ultraviolet rays is 23.7, and the relative value of the carbonylated protein amount of the helipyrone A 0.1% formula group is 25.7, which is the same degree. It was. Therefore, helipyrone A significantly suppresses the production of carbonylated protein associated with ultraviolet irradiation.
항산화작용을 갖는 β-카로틴 섭식군은 카르보닐화 단백질의 생성 억제효과는 그다지 인정되지 않았다.Antioxidant β-carotene feeding group was not recognized the inhibitory effect of the production of carbonylated protein.
자외선 조사 10주간의 β-카로틴을 0.05% 배합한 MF-1식군의 카르보닐화 단백질량의 상대값은 153.1, 자외선 조사 10주간의 β-카로틴을 0.01% 배합한 MF-1식군의 카르보닐화 단백질량의 상대값은 190.7이었다.The carbonylated protein of the MF-1 group that contained 0.05% of β-carotene for 10 weeks of ultraviolet irradiation was 153.1, and the carbonylated of the MF-1 group that contained 0.01% of β-carotene for 10 weeks of UV irradiation. The relative value of protein amount was 190.7.
[자외선 조사에 수반하는 피부조직 중 8-히드록시-2'-데옥시구아노신(8-OH dG)의 생성 억제][Inhibition of Production of 8-hydroxy-2'-deoxyguanosine (8-OH dG) in Skin Tissue with UV Irradiation]
8-OH dG는 면역조직화학적 수법을 사용해서 측정하였다. 동물의 해부시에 피부조직 배부의 꼬리부착 부분으로부터 머리를 향해 2 ㎝, 요추로부터 우측으로 0.5 ㎝ 부위의 피부 1 ㎠를 잘라내어, 부앙 고정, 및 파라핀 포매하여 피부조직을 보존하였다. 3 ㎛ 두께의 절편을 적절히 제작하고, 탈 파라핀, 친수화는 공지의 방법을 토대로 하여 실시하였다. 항원 부활화(賦活化)는 0.01 M 구연산 완충액(pH=6.0) 중에서 5분간 마이크로파 처리를 실시하였다. 실온까지 냉각 후, 상온하 0.3% 과산화수소 함유 메탄올에서 20분 반응시켜 내인성 퍼옥시다아제를 저해하였다. 수세, 10 mM PBS(-) 세정 후, 토끼 혈청 75배 10 mM PBS(-) 희석 용액에서 5분간 마이크로파 처리를 실시하여 블로킹, 혈청을 떨어뜨려 1차 항체(N 45.1: 닛켄 세일(주)제)를 5 ㎍/㎖에서 20분간 마이크로파 처리에 의해 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, 비오틴화 2차 항체(비오틴화 토끼 면역 글로불린 M; DAKO제)를 300배 희석한 것을 5분간 마이크로파 처리로 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, ABC 시약(ABC-HRP; Vectastain제)을 5분간 마이크로파 처리에 의해 반응시켰다. 발색시약으로서 DAB(3,3-디아미노벤지딘 테트라히드로 클로라이드: DAKO제)를 사용하여 3분 30초 상온하에서 반응시켰다. 수세 후, 공지의 방법을 토대로 하여 탈수, 봉입(封入) 처리를 행하였다. 현미경하에서 피부조직의 염색상황을 관찰하고, Adobe Photoshop을 사용하여 화상을 읽어들여, 화상 중 일정 면적 중의 염색 개소를 NIH Imaging으로 수치화하였다. 결과를 도 5에 나타낸다.8-OH dG was measured using immunohistochemical techniques. At the time of dissection of the animal, 1
그 결과, 자외선 조사 10주간+MF-1(대조)식군에서는 8-OH dG의 상대값은 5.89인 것에 비해, 자외선 조사 10주간+헬리피론 A 배합의 MF-1식군에서는 헬리피론 A 0.1% 배합에서 8-OH dG량의 상대값은 0.87, 0.05% 배합에서 8-OH dG량의 상대값은 0.91, 0.01% 배합에서 8-OH dG의 상대값은 1.10으로, 8-OH dG량의 생성이 15/100~19/100로 억제되었다. 자외선을 조사하지 않고 10주간 경과한 MF-1(대조)식군의 8-OH dG량의 상대값 1.00과 비교하여, 자외선 조사 헬리피론 A 0.05% 배합식군, 0.1% 배합식군의 8-OH dG량의 상대값은 더욱 낮은 값이다. 따라서, 헬리피론 A는 자외선 조사에 수반하는 8-OH dG의 생성을 현저히 억제하고 있다.As a result, the relative value of 8-OH dG in the 10-week UV irradiation + MF-1 (control) diet group was 5.89, whereas 0.1% of helipyron A in the MF-1 diet group of the UV irradiation 10-week + Helicyron A combination The relative value of 8-OH dG is 0.87, and the relative value of 8-OH dG is 0.91 at 0.05%, and the relative value of 8-OH dG is 1.10 at 0.01%. It was suppressed from 15/100 to 19/100. Compared with the relative value of 1.00 of the amount of 8-OH dG of the MF-1 (control) formula group which had elapsed for 10 weeks without irradiating ultraviolet rays, the amount of 8-OH dG of the group of the 0.05% UV-Helipyron A formula and the 0.1% formula The relative value of is even lower. Therefore, helipyrone A significantly suppresses the generation of 8-OH dG accompanying ultraviolet irradiation.
또한, 항산화작용을 갖는 β-카로틴 섭식군은 8-OH dG의 생성 억제효과를 나타내지 않았다.In addition, the β-carotene feeding group having antioxidant activity did not show the inhibitory effect of 8-OH dG production.
자외선 조사 10주간의 β-카로틴을 0.05% 배합한 MF-1식군의 8-OH dG량의 상대값은 5.2, 자외선 조사 10주간의 β-카로틴을 0.01% 배합한 MF-1식군의 8-OH dG량의 상대값은 6.3이었다.The relative value of 8-OH dG amount of the MF-1 group which contained 0.05% of β-carotene for 10 weeks of ultraviolet irradiation was 5.2 and 8-OH of the MF-1 group which contained 0.01% of β-carotene for 10 weeks of ultraviolet irradiation. The relative value of the amount of dG was 6.3.
[자외선 조사에 수반하는 피부조직 중 과산화지질의 생성 억제][Inhibition of Production of Lipid Peroxide in Skin Tissue Associated with Ultraviolet Irradiation]
피부조직에 있어서 TBARS(티오바르비투르산 반응생성물, n㏖/g wet weight)를 형광분석으로 측정하였다. 각 조직의 습중량 약 200 ㎎을 칭량하고, 1.15% KCl 1 ㎖로 호모지네이트 후, 1/12 N 황산 4 ㎖, 10% 텅스텐인산 0.5 ㎖를 순차 첨가하여, 3,000 rpm으로 10분간 원심분리를 행하였다. 상청의 협잡물을 제거하고, TBA 시약(티오바르비투르산/초산 완충액)을 첨가하여, 비등 탕욕 중에서 1시간 가열 반응하였다. TBARS의 정량용으로 별도 1,1,3,3-테트라에톡시프로판을 첨가한 시료로 TBA 반응을 행하고, 검량선을 제작하였다. 결과를 도 6에 나타낸다.TBARS (thiobarbituric acid reaction product, nmol / g wet weight) in skin tissue was measured by fluorescence analysis. Approximately 200 mg of the wet weight of each tissue was weighed, homogenated with 1 ml of 1.15% KCl, 4 ml of 1/12 N sulfuric acid and 0.5 ml of 10% tungsten phosphate were added sequentially, followed by centrifugation at 3,000 rpm for 10 minutes. It was done. The supernatant was removed, TBA reagent (thiobarbituric acid / acetic acid buffer) was added, and it heated and reacted for 1 hour in a boiling water bath. TBA reaction was performed with the sample which added 1,1,3,3- tetraethoxy propane separately for the determination of TBARS, and the analytical curve was produced. The results are shown in Fig.
가열 반응 종료 후, 빙냉으로 실온에 되돌리고, n-부탄올을 5 ㎖ 첨가하여 교반한 후에 3,000 rpm으로 10분간의 조건에서 원심분리하여, 상층의 n-부탄올층을 회수하고, 형광분석(Ex 515 ㎚, Em 553 ㎚)에 제공하였다. 형광 강도계는 HITACHI F-2000을 사용하였다.After the completion of the heating reaction, the mixture was returned to room temperature by ice-cooling, 5 ml of n-butanol was added thereto, stirred, and centrifuged at 3,000 rpm for 10 minutes to recover the upper n-butanol layer, followed by fluorescence analysis (Ex 515 nm). , Em 553 nm). The fluorescence intensity meter used HITACHI F-2000.
그 결과, 자외선 조사 10주간+MF-1(대조)식군에서는 조직 중 과산화지질량이 50.8 n㏖/㎎인 것에 비해, 자외선 조사 10주간+헬리피론 A 배합의 MF-1식군에서는 헬리피론 A 0.1% 배합에서 조직 중 과산화지질량이 30.9 n㏖/㎎, 0.05% 배합에서 조직 중 과산화지질량이 33.7 n㏖/㎎, 0.01% 배합에서 조직 중 과산화지질량이 44.8 n㏖/㎎으로서, 과산화지질의 생성이 6/10~9/10로 억제되었다. 자외선 조사 10주간+헬리피론 A 0.1% 배합식군 및 0.05% 배합식군의 과산화지질량은 자외선을 조사하지 않고 10주간 경과한 MF-1(대조)식군의 조직 중 과산화지질량 30.2 n㏖/㎎과 동일 정도이다. 따라서, 헬리피론 A는 자외선 조사에 수반하는 과산화지질의 생성을 현저히 억제하고 있다.As a result, in the MF-1 meal group of 10 weeks of ultraviolet irradiation + Helicyron A combination, 0.1% of helipyron A in the 10-hour UV irradiation + MF-1 (control) diet group compared to 50.8 nmol / mg of the lipid peroxide in the tissue. 30.9 nmol / mg of lipid peroxide in the tissue in the formulation, 0.05% lipid peroxide in the tissue in the 0.05% formulation, and 44.8 nmol / mg of lipid peroxide in the tissue in the 0.01% formulation. / 10 to 9/10 was suppressed. The mass of peroxide in the 0.1% and 0.05% group of the 10% helipadron A group and the 0.05% group of the UV irradiation group contained 30.2 nmol / mg of peroxide in the tissues of the MF-1 (control) group after 10 weeks without irradiation with UV. It is about the same. Therefore, helipyrone A significantly suppresses the generation of lipid peroxide accompanying ultraviolet irradiation.
또한, 항산화작용을 갖는 β-카로틴 섭식군의 과산화지질의 생성억제효과는 거의 없었다.In addition, there was little effect of inhibiting the production of lipid peroxide of the β-carotene feeding group having antioxidant activity.
자외선 조사 10주간의 β-카로틴을 0.05% 배합한 MF-1식군의 과산화지질량은 46.9 n㏖/㎎, 자외선 조사 10주간의 β-카로틴을 0.01% 배합한 MF-1식군의 과산화지질량은 51.1 n㏖/㎎이었다.The mass peroxide of the MF-1 group with 0.05% of β-carotene for 10 weeks of UV irradiation was 46.9 nmol / mg, and the mass peroxide of the MF-1 group with 0.01% of β-carotene for 10 weeks of UV irradiation was 51.1 nmol / mg.
[ESR법에 의한 일산화질소 소거능의 평가][Evaluation of Nitric Oxide Scavenging Capacity by ESR Method]
100 μM의 SNAP(S-니트로소-N-아세틸-D,L-페니실라민, 도진도제)에 대한, 헬리피론 A와 산화방지제로서 기지의 (-)카테킨(Sigma제)의 일산화질소 소거능을 비교하였다. Nitric oxide scavenging activity of (-) catechin (manufactured by Sigma), known as helipyron A and antioxidant, for 100 μM SNAP (S-nitroso-N-acetyl-D, L-penicillamine, dopant) Was compared.
스핀트랩제에는 N-메틸-D-글루카민-디티오카바메이트(이하, MGD라고 한다. 라보텍(주)으로부터 구입)와 황산철(II) 수용액을 혼합하여 조제한 (MGD)2-Fe2 + 복합체를 사용하였다. 이 복합체는 일산화질소와 반응하여 (MGD)2-Fe2 +-NO의 복합체를 형성함으로써 ESR 스펙트럼 강도를 발생시키는 점으로부터, 일산화질소 소거제의 각각의 농도에 있어서의 ESR 스펙트럼을 측정함으로써 일산화질소의 소거능을 측정하였다.The spin trapping agent (MGD) 2 -Fe 2 prepared by mixing N-methyl-D-glucamine-dithiocarbamate (hereinafter referred to as MGD, purchased from Labotech Co., Ltd.) and an aqueous solution of iron (II) sulfate. + Complex was used. This complex reacts with nitrogen monoxide to form a complex of (MGD) 2 -Fe 2 + -NO to generate an ESR spectral intensity, thereby measuring the ESR spectrum at each concentration of the nitrogen monoxide scavenger. The scavenging ability of was measured.
50 mM 황산철(II)·2 수화물 용매: 증류수 100 μL(최종 농도 5 mM), 50 mM MGD 용매 PBS(pH 7.4) 100 μL(최종 농도 5 mM), 피험물질 용매: 10% 아세토니트릴 100 μL, 100 mM 인산 완충액 699 μL, 100 mM SNAP 용매 0.1 M 수산화나트륨 1 μL(최종 농도 100 μM)를 순차 1.5 ㎖ 용량의 에펜도르프 튜브(eppendorf tube)에 첨가하고, SNAP 첨가시로부터 10분간 25℃에서 교반 반응하였다.50 mM iron sulfate (II) 2 hydrate solvent: 100 μL of distilled water (
10분간 25℃의 반응에서 SNAP로부터 일산화질소가 방출되어, (MGD)2-Fe2 +-NO의 시그널 강도비=1:1:1의 3개의 피크로 구성되어 있었다. 이 시그널 강도가 피험물질에 의해 어느 정도 증감하는지로 일산화질소 소거능을 평가하였다. 구체적으로는, 피험물질을 첨가하지 않는 대조의 시그널 강도(C)를 기준으로, 피험물질을 첨가하였을 때의 시그널 강도(S)로부터 다음 식에 의해 일산화질소 소거율을 구하여, 도 7에 나타내었다.In the reaction of 25
일산화질소 소거율=(1-S/C)×100(%)Nitrogen monoxide scavenging ratio = (1-S / C) * 100 (%)
그 결과, 헬리피론 A는 25 μM~200 μM의 범위에서 농도의존적으로 일산화질소 소거율이 향상되어(25 μM에서 32.4%, 50 μM에서 52.6%, 100 μM에서 63.6%, 200 μM에서 80.1%), IC50 농도 51.4 μM였던 것에 비해, (-)카테킨은 50 μM, 100 μM에서는 일산화질소 소거율이 각각 5.6%, 11.7%에 지나지 않으며, 250 μM에서 31.4%, 500 μM에서 47.4%의 일산화질소 소거율이었다. IC50 농도는 547 μM로 계산되었다.As a result, helipyrone A improved nitric oxide scavenging rate in a concentration-dependent range from 25 μM to 200 μM (32.4% at 25 μM, 52.6% at 50 μM, 63.6% at 100 μM, 80.1% at 200 μM). Compared to the IC50 concentration of 51.4 μM, the nitrate scavenging rate was only 5.6% and 11.7% at 50 μM and 100 μM, respectively, and 31.4% at 250 μM and 47.4% at 500 μM. Was rate. IC50 concentration was calculated to be 547 μΜ.
금번 사용한 기기 및 기기의 조건 설정을 이하에 나타낸다.The setting of the apparatus and apparatus used this time is shown below.
기기: JEOL JES TE200, X-band ESR 장치(100 K㎐, 일본전자사제)Instrument: JEOL JES TE200, X-band ESR device (100 KHz, Japan Electronics Corporation)
기기의 조건 설정:Set conditions for your device:
센터 필드(center field): 335.0±5.0 mT,Center field: 335.0 ± 5.0 mT,
마이크로파 전력(microwave power): 4 ㎽,Microwave power: 4 kW,
변조 진폭(modulation amplitude): 0.1 mT,Modulation amplitude: 0.1 mT,
게인(gain): 500,Gain: 500,
시상수(time constant): 0.1초,Time constant: 0.1 sec,
스캐닝 타임(scanning time): 1분Scanning time: 1 minute
[비색법(Griess법)에 의한 일산화질소 소거능]Nitric Oxide Scavenging Capacity by Colorimetric Method (Griess Method)
용액 중에 존재하는 일산화질소는 수용액 중에서 극히 불안정하므로, ESR법 외에, 일산화질소의 산화물인 아질산 이온을 측정함으로써 일산화질소량을 간접적으로 평가하였다. 기지의 항산화물질인 (-)카테킨, 말톨, p-쿠마린산에 대해서도 평가하여, 헬리피론 A와 비교하였다. Griess법에 의한 측정은 NO2/NO3 Assay Kit-CII(Colorimetric)(도진도제)를 사용하였다.Since nitrogen monoxide present in the solution is extremely unstable in an aqueous solution, in addition to the ESR method, the amount of nitrogen monoxide was indirectly evaluated by measuring nitrite ions, which are oxides of nitrogen monoxide. Known antioxidants (-) catechin, maltol and p-coumarinic acid were also evaluated and compared with helipyrone A. The measurement by the Griess method used the NO 2 / NO 3 Assay Kit-CII (Colorimetric) (propellant).
일산화질소 발생제로서, NOC-5(1-히드록시-2-옥소-3-(3-아미노프로필)-3-이소프로필-1-트리아젠)(도진도제)를 사용하고, 사용 직전까지 0.1 N 수산화나트륨의 알칼리 용액으로 -20℃ 냉동 보존하였다. Kit 중의 완충액(pH=7.6, 이하 「완충액」)에 의해 10,000배 희석하여 100 μM의 농도로 조정함으로써 일산화질소를 발생시켰다. 일산화질소 공여체로서 개발된 NOC-5는 알칼리 용액 중에서는 안정하나, 중성 및 산성 조건하에서는 일산화질소를 생성하는 불안정한 화합물(25도, pH 7.4 조건하에서 반감기 25분)이다.As the nitrogen monoxide generator, NOC-5 (1-hydroxy-2-oxo-3- (3-aminopropyl) -3-isopropyl-1-triazene) (the scavenger) is used until immediately before use. Cryopreservation was -20 ° C with an alkaline solution of 0.1 N sodium hydroxide. Nitrogen monoxide was generated by diluting 10,000 times with a buffer solution (pH = 7.6, hereinafter "buffer") in a kit and adjusting to a concentration of 100 µM. NOC-5, developed as a nitric oxide donor, is a labile compound (25 degrees,
시판의 바닥이 평평한 96 웰 플레이트에 피험물질 용매: 1% 아세토니트릴을 포함하는 완충액(pH=7.6) 40 μL를 피험물질의 농도를 변화시켜 첨가하였다. 그 후, 완충액(pH=7.6)을 20 μL 첨가하고, 100 μM의 NOC-5 용액 40 μL를 첨가하여 2시간 25℃에서 반응시켰다. 반응 종료 후, Kit 중의 Griess 시약 A를 50 μL 첨가하여 5분 방치하고, 계속해서 Griess 시약 B를 50 μL씩 첨가하고 10분 방치하여 정색(呈色)반응을 행하였다. 멀티플레이트 리더로 540 ㎚의 흡광도를 측정하였다. 각 피험물질의 첨가 농도에 있어서의 흡광도를 S540, 피험물질을 포함하지 않는 대조의 흡광도를 C540, 피험물질 및 NOC-5를 포함하지 않는 블랭크의 흡광도를 B540으로 하여 이하의 식으로 일산화질소 소거율(%)을 산출하고, 표 2, 도 8에 나타내었다.To a 96-well plate with a flat bottom, 40 μL of a test solution (pH = 7.6) containing 1% acetonitrile was added at varying concentrations of the test substance. Thereafter, 20 µL of a buffer solution (pH = 7.6) was added, and 40 µL of a 100 µM NOC-5 solution was added and reacted at 25 ° C for 2 hours. After the reaction was completed, 50 μL of Griess reagent A in the kit was added and left to stand for 5 minutes. Then, 50 μL of the Griess reagent B was added thereto, and left for 10 minutes to conduct a color reaction. The absorbance at 540 nm was measured with a multiplate reader. The absorbance at the concentration of each test substance was S 540 , the absorbance of the control without the test substance was C 540 , and the absorbance of the blank without the test substance and NOC-5 was B 540 . The nitrogen clearance rate (%) was computed and shown in Table 2 and FIG.
일산화질소 소거율(%)=100×(1-(S540-B540)/(C540-B540)Nitric oxide scavenging rate (%) = 100 × (1- (S 540 -B 540 ) / (C 540 -B 540 )
검량선은 NOC-5 용액 대신에 아질산나트륨 용액 0~100 μM의 농도역에서 설정한 검체의 흡광도로부터 제작하여, 용액 중 아질산 이온 농도를 구하였다. 이 아질산 이온 농도로부터 NOC-5 용액으로부터 발생한 일산화질소 농도를 구할 수 있다. 일산화질소 소거능의 강도는 본 시험계에서 50% 소거하는 농도(IC50, μM)로 비교하였다.The calibration curve was produced from the absorbance of the sample set in the concentration range of 0-100 μM of sodium nitrite solution instead of the NOC-5 solution, and the concentration of nitrite ion in the solution was determined. The nitrogen monoxide concentration generated from the NOC-5 solution can be obtained from the nitrite ion concentration. The intensity of nitric oxide scavenging ability was compared with the concentration (IC50, μM) which is 50% scavenging in this test system.
100 μM의 NOC-5 용액으로부터 47.0 μM의 일산화질소가 아질산 이온으로서 생성된다. 이때, 피험물질 첨가에 의한 흡광도의 저하, 즉, 일산화질소의 소거활성이 인정되었다.47.0 μM of nitrogen monoxide is produced as nitrite ion from 100 μM of NOC-5 solution. At this time, the decrease in absorbance due to the addition of the test substance, that is, the scavenging activity of nitrogen monoxide was recognized.
헬리피론 A는 50 μM~400 μM의 범위에서 농도의존적으로 일산화질소의 소거능이 인정되고, IC50 농도는 36.7 μM였다. 한편, (-)카테킨, 말톨, p-쿠마린산의 IC50 농도는 190.0 μM, 94.0 μM, 187.4 μM였다. 헬리피론 A의 우수한 일산화질소 소거능이 확인되었다.In the range of 50 μM to 400 μM of helipyrone A, nitric oxide scavenging ability was recognized and the IC50 concentration was 36.7 μM. On the other hand, the IC50 concentrations of (-) catechin, maltol and p-coumarinic acid were 190.0 µM, 94.0 µM, and 187.4 µM. Excellent nitric oxide scavenging ability of Helicyron A was confirmed.
이상의 결과로부터, 본 발명의 헬리피론 A가 일산화질소를 소거하는 것이 명확해져, 혈관계, 신경계, 면역계의 약제로서 유용하다고 생각할 수 있다. 이 헬리피론 A는 생체 내에 존재하는 과잉의 일산화질소를 소거하여, 정상적인 일산화질소 농도로 하는 작용 및 일산화질소가 과잉으로 발생하는 것이 예측되는 경우에 사전에 투여하여 생체 내에 과잉의 일산화질소가 발생하는 것을 방지하는 작용을 가지고 있다. 즉, 본 명세서에 있어서 헬리피론 A의 일산화질소 소거능이란, 생체 내에 존재하는 모든 일산화질소를 완전히 소거하는 것을 말하는 것이 아니라, 생체 내에 있는 과잉의 일산화질소를 소거하여 생체의 유지에 적절한 양이 되도록 조절하는 것을 말한다.From the above results, it is clear that helipyrone A of the present invention eliminates nitrogen monoxide, and it can be considered to be useful as a drug for the vascular system, the nervous system, and the immune system. This helipyron A eliminates excess nitrogen monoxide present in the living body, and is administered in advance when it is expected to act as a normal nitrogen monoxide concentration and excessive generation of nitrogen monoxide. It has a function to prevent it. In other words, in the present specification, the nitric oxide scavenging ability of the helipirone A does not mean completely erasing all of the nitrogen monoxide present in the living body, but is controlled so as to remove the excess nitrogen monoxide in the living body so as to be suitable for maintenance of the living body. I say that.
[비색법에 의한 과산화아질산염 소거능]Nitrite Peroxide Scavenging Activity by Colorimetric Method
헬리피론 A의 과산화아질산염 소거능은 Griess법에 의해, NO2/NO3 Assay Kit-CII(Colorimetric)(도진도제)를 사용하여 측정하였다.The nitrite peroxide scavenging ability of helipyrone A was measured by Griess method using NO 2 / NO 3 Assay Kit-CII (Colorimetric).
기지의 항산화물질인 (-)카테킨, 말톨, p-쿠마린산에 대해서도 평가하여, 헬리피론 A와 비교하였다.Known antioxidants (-) catechin, maltol and p-coumarinic acid were also evaluated and compared with helipyrone A.
시판의 바닥이 평평한 96 웰 플레이트에 피험물질 용매: 1% 아세토니트릴을 포함하는 완충액(pH=7.6) 40 μL를 피험물질의 농도를 변화시켜 첨가하였다. 그 후, 각각의 웰에 Kit 중의 환원효소 10 μL, 및 보효소 10 μL를 첨가하였다.To a 96-well plate with a flat bottom, 40 μL of a test solution (pH = 7.6) containing 1% acetonitrile was added at varying concentrations of the test substance. Thereafter, 10 μL of reductase and 10 μL of coenzyme in Kit were added to each well.
과산화아질산염 발생제로서 SIN-1(3-(4-모르폴리닐)시드노니민 염산염) 50 μM를 40 μL 첨가하여 37℃에서 2시간 반응시켰다. 반응 종료 후, Kit 중의 Griess 시약 A를 50 μL 첨가하여 5분 방치하고, 계속해서 Griess 시약 B를 50 μL씩 첨가하고 10분 방치하여 정색반응을 행하였다. 멀티플레이트 리더로 540 ㎚의 흡광도를 측정하였다. 피험물질의 흡광도를 S540, 피험물질을 포함하지 않는 대조의 흡광도를 C540, 피험물질 및 SIN-1을 포함하지 않는 블랭크의 흡광도를 B540으로 하여 이하의 식으로 과산화아질산염 소거율(%)을 산출하고, 표 3, 도 9에 나타내었다.40 μL of SIN-1 (3- (4-morpholinyl) sidnonimine hydrochloride) was added as a nitrite peroxide generator and reacted at 37 ° C. for 2 hours. After the reaction was completed, 50 μL of Griess reagent A in the kit was added and left to stand for 5 minutes. Then, 50 μL of the Griess reagent B was added thereto, followed by 10 minutes of color reaction. The absorbance at 540 nm was measured with a multiplate reader. The absorbance of the test substance was S 540 , the absorbance of the control without test substance was C 540 , and the absorbance of the blank without test substance and SIN-1 was B 540 . Was calculated and shown in Table 3, FIG.
과산화아질산염 소거율(%)=100×(1-(S540-B540)/(C540-B540)Peroxide nitrite scavenging rate (%) = 100 × (1- (S 540 -B 540 ) / (C 540 -B 540 )
검량선은 SIN-1 용액 대신에 질산나트륨 용액 0~100 μM 의 농도역에서 설정한 검체의 흡광도로부터 제작하여, 용액 중 질산 이온 농도를 구하였다. 이 질산 이온 농도로부터 SIN-1 용액으로부터 발생한 과산화아질산염 농도를 구할 수 있다. 과산화아질산염 소거능의 강도는 본 시험계에서 50% 소거하는 농도(IC50, μM)로 비교하였다.The calibration curve was produced from the absorbance of the sample set in the concentration range of 0-100 μM of sodium nitrate solution instead of the SIN-1 solution, and the concentration of nitrate ions in the solution was determined. From this concentration of nitrate ions, the concentration of nitrite peroxide generated from the SIN-1 solution can be obtained. The intensity of nitrite peroxide scavenging ability was compared with the concentration of 50% scavenging (IC50, μM) in this test system.
그 결과, 대조에서는 50 μM의 SIN-1으로부터 과산화아질산염이 8.18 μM 발생하고, 그 과산화아질산염을 50% 소거하는 IC50 농도에 대해서, 헬리피론 A는 24.04 μM인 것에 대해, 말톨 31.84 μM, p-쿠마린산 31.49 μM, (-)카테킨 705.6 μM가 되어, 헬리피론 A가 우수한 과산화아질산염 소거능을 나타내었다. As a result, in the control, 8.18 μM of nitrite was generated from 50 μM of SIN-1, and for heliconon A of 24.04 μM with respect to an IC50 concentration of 50% scavenging of the nitrite, maltol 31.84 μM and p-coumarin The acid became 31.49 μM and (-) catechin 705.6 μM, showing that Helipyron A showed excellent nitrite peroxide scavenging ability.
과산화아질산염은 생체 내에서 일산화질소와 슈퍼옥사이드 음이온의 반응에서 발생하고, 강력한 산화작용 및 생체 손상, 염증을 야기한다. 과산화아질산염 소거활성을 나타내는 헬리피론 A는, 산화방지제로서 생체에 있어서의 염증을 억제하고, 생체 성분을 보호하는 기능을 발휘한다.Nitrite peroxide occurs in the reaction of nitrogen monoxide and superoxide anion in vivo, causing strong oxidation, damage to the body, inflammation. Helipyron A, which exhibits nitrite peroxide scavenging activity, functions as an antioxidant to suppress inflammation in a living body and to protect a biological component.
[티로시나아제 활성 저해작용의 측정][Measurement of Tyrosinase Activity Inhibition]
바닥이 평평한 96 웰 플레이트에 피험물질 용액 100 μL를 첨가하고, 600 units/㎖의 버섯 유래의 티로시나아제 용액 10 μL를 첨가하여, 30℃에서 10분간 배양하였다. 그 후, 사전에 30℃로 데워놓은 6 mM의 L-DOPA(L-β-(3,4-디히드록시페닐)알라닌) 용액 100 μL를 첨가하고, 30℃에서 40분간 진탕하면서 배양하였다. 피험물질의 용매는 1% 아세토니트릴 함유 100 mM 숙신산 완충액(pH 5.5)을 사용하고, 티로시나아제, L-DOPA의 용매는 100 mM 숙신산 완충액(pH 5.5)을 사용하였다. 진탕 후, 멜라닌량의 지표인 475 ㎚의 파장에서 흡광도를 측정하고, 이 값을 S475로 하였다. 피험물질 무첨가의 경우를 대조(C), 이 흡광도를 C475, L-DOPA 무첨가의 경우를 샘플 블랭크(SB), 이 흡광도를 SB475, 샘플과 L-DOPA 무첨가의 경우를 대조 블랭크(CB), 이 흡광도를 CB475로 하고, 다음 식에 의해 티로시나아제 저해율을 산출하였다. 양성 대조로서 알부틴(도쿄 카세이 고교(주)제)을 사용하였다.100 μL of the test substance solution was added to a flat bottom 96-well plate, and 10 μL of a tyrosinase solution derived from 600 units / ml of mushroom was added thereto, followed by incubation at 30 ° C. for 10 minutes. Thereafter, 100 µL of a 6 mM L-DOPA (L-β- (3,4-dihydroxyphenyl) alanine) solution previously warmed to 30 ° C was added, and incubated with shaking at 30 ° C for 40 minutes. 100 mM succinic acid buffer (pH 5.5) containing 1% acetonitrile was used as the solvent of the test substance, and 100 mM succinic acid buffer (pH 5.5) was used as the solvent of tyrosinase and L-DOPA. After shaking, the absorbance was measured at the wavelength of 475 nm which is an index of melanin amount, and this value was set to S 475 . In the case of no test substance added, control (C), the absorbance of C 475 , L-DOPA-free sample blank (SB), the absorbance of SB 475 , and sample and L-DOPA-free control blank (CB) And this absorbance was set to CB 475 , and the tyrosinase inhibition rate was computed by following Formula. Arbutin (made by Tokyo Kasei Kogyo Co., Ltd.) was used as a positive control.
티로시나아제 활성 저해율%=100×{1-(S475-SB475)/(C475-CB475)}% Inhibition of tyrosinase activity = 100 × {1- (S 475 -SB 475 ) / (C 475 -CB 475 )}
이 결과, 첨가 농도 1 mM에 있어서의 헬리피론 A와 알부틴의 티로시나아제 저해율은, 헬리피론 A에서는 36.34%였던 것에 비해, 알부틴은 25.77%였던 점으로부터, 헬리피론 A는 알부틴보다도 우수한 티로시나아제 저해활성을 갖고, 헬리피론 A가 미백작용을 나타내는 것을 알 수 있다.As a result, the tyrosinase inhibition rate of helipyron A and arbutin at an addition concentration of 1 mM was 25.77% in arbutin, compared to 36.34% in helipyron A, so that helipyron A was better in tyrosinase than arbutin. It can be seen that heliopyron A has an inhibitory activity and exhibits a whitening effect.
[마우스 피부에 있어서의 티로시나아제 유전자 발현 해석][Tyrosinase Gene Expression Analysis in Mouse Skin]
마우스에 헬리피론 A를 섭식시켰을 때, 티로시나아제를 코드하는 유전자의 발현을 마우스 피부에서 측정하였다.When mice were fed Helipyron A, expression of the gene encoding tyrosinase was measured in mouse skin.
I. 실험동물I. Experimental Animal
I-1. 종·계통·성별: 종: 마우스, 계통: Hos:HR1(누드 마우스), 성별: 암컷I-1. Species, strain, and gender: Species: mouse, strain: Hos: HR1 (nude mouse), Gender: female
I-2. 사육 개시주령: 5주령(1주간 사육 후 6주령부터 자외선 조사 시험을 개시하였다)I-2. Start of breeding week: 5 weeks of age (starting ultraviolet irradiation test after 6 weeks of breeding for 1 week)
I-3. 미생물 등급: SPFI-3. Microbial Grade: SPF
I-4. 브리더: 시미즈 실험재료 주식회사I-4. Breather: Shimizu Experiment Materials Co., Ltd.
II. 사육 환경II. Breeding environment
설정 온습도: 24±1℃, 상대습도 55±5%Set temperature and humidity: 24 ± 1 ℃, relative humidity 55 ± 5%
공기조절설비: 올후레쉬 방식Air Conditioning Equipment: All Fresh
조명시간: 12시간 자동 점등·소등 방식Illumination time: 12 hours auto on / off
사육설비: 플라스틱제 케이지 5마리/케이지Breeding equipment: 5 plastic cages / cage
사료: 분말 멸균사료 MF-1(오리엔탈 효모공업(주))을 자유 섭취, 또는 MF-1에 헬리피론 A를 0.1 중량% 혼합한 사료도 별도 조제하였다.Feed: A powder sterilized feed MF-1 (Oriental Yeast Industries Co., Ltd.) was freely ingested, or a feed obtained by mixing 0.1 wt% of helipyron A with MF-1 was separately prepared.
시험대상물의 투여: 분말 혼합사료로서 자유 섭취시켰다. 해부 18시간 전부터 절식시켰다.Administration of Test Subjects: Free intake as a powdered blend.
급수: 멸균을 끝낸 수돗물을 자유 섭취Water supply: free intake of sterile tap water
III. 해부III. Anatomy
해부 18시간 전부터 절식시킨 개체의 체중 측정, 피부수분량을 측정 후, 마취제 넴부탈(40 ㎎/㎏)의 복강내 투여에 의해 마취를 도입하였다.Anesthesia was introduced by intraperitoneal administration of the anesthetic nembutal (40 mg / kg) after measuring the body weight and skin moisture of the fasted subject 18 hours before dissection.
복부를 절개하고, 심장으로부터 헤파린 채혈을 행하였다. 다음으로 장기에 대해서 육안적 관찰을 행한 후에 간장, 후두부로부터 둔부에 있어서 배부 전체의 피부를 적출하였다. 배부 피부에 관해서는, 피부조직 배측의 꼬리부착 부분으로부터 머리를 향해 2 ㎝, 요추로부터 우측으로 0.5 ㎝ 부위의 피부 1 ㎠를 잘라내어, 부앙 고정, 및 파라핀 포매하여 피부조직을 보존하였다. 그 외의 배부 피부는 신속히 알루미늄 호일에 넣고 액체 질소로 급속하게 동결하여 -80℃에서 장기 보존하였다.The abdomen was dissected and heparin blood was collected from the heart. Next, after visual observation was performed on the organs, the entire skin of the abdomen was removed from the liver and the larynx. As for the back skin, 1
[유전자 발현 해석에 관한 시험][Test about Gene Expression Analysis]
각 군 2마리의 배부 피부를 선택하여, 유전자 발현 해석용 Total RNA 샘플을 추출하였다. 배부 피부를 액체 질소 존재하에서 세절 분쇄하고, 습중량 수십 ㎎마다 1.5 ㎖ 용량의 에펜도르프 튜브에 분주(分注)하였다. Total RNA 추출은 RNase easy mini kit(QIAGEN제)를 사용하고, 통상의 프로토콜에 따랐다.Two dormant skins of each group were selected and total RNA samples for gene expression analysis were extracted. The dorsal skin was triturated in the presence of liquid nitrogen and dispensed into 1.5 ml Eppendorf tubes every tens of mg of wet weight. Total RNA extraction was carried out using a RNase easy mini kit (produced by QIAGEN) and followed the conventional protocol.
추출한 Total RNA에 대해서 Affymetrix사 추장(推奬)하는 프로토콜에 따른 처리를 행한 후, DNA 마이크로어레이법에 의해 피부조직에 있어서의 발현 패턴을 조사하였다. 구체적으로는, 추출한 total RNA로부터, 「SUPERSCRIPT choice system for cDNA synthesis」(상품명, Invitrogen사제)를 사용하여 cDNA를 합성하고, 이 cDNA를 주형(template)으로 하여 「Bio Array High Yield RNA Transcript Labeling Kit」(상품명, Enzo Diagnostics사제)를 사용하여 비오틴 표지한 cRNA를 시험관 내에서 합성하였다. 그리고, 이 cRNA를 단편화한 후, DNA 마이크로어레이(상품명 「Gene Chip Mouse Expression Array 430A」(Affymetrix사제))와 「하이브리다이제이션 오븐」(상품명, Affymetrix사제)으로 하이브리다이제이션을 행하고, R-피코에리트린-스트렙토아비딘과의 반응 및 세정 조작을 「Fluidics station」(상품명, Affymetrix사제)으로 행한 후, 형광 강도를 「Gene Array Scanner」(상품명, Affymetrix사제)로 측정하여, 관련 유전자 발현량의 해석을 행하였다. 또한, 상기 DNA 마이크로어레이의 검출 감도는 1:100,000이고, 이것은 마우스 total RNA 샘플 중에 마우스 cDNA 클론 유래의 표지를 끝낸 전사산물을 첨가하여 검출함으로써 측정하고 있다. 본 시험에서 사용한 마우스 피부 유래 total RNA에 대해서 22,690 유전자가 검출되어, 유전자 발현 증감의 해석에 사용하였다. 그 중에서 티로시나아제는 Probe ID: 1448821_at으로 코드되고, 그 형광 강도로부터 유전자 발현 강도의 비율을 구하였다.The extracted Total RNA was subjected to a treatment according to Affymetrix's recommended protocol, and the expression pattern in the skin tissue was examined by DNA microarray method. Specifically, cDNA is synthesized from the extracted total RNA using "SUPERSCRIPT choice system for cDNA synthesis" (trade name, manufactured by Invitrogen), and the cDNA is used as a template for "Bio Array High Yield RNA Transcript Labeling Kit". Biotin-labeled cRNA was synthesized in vitro using (trade name, manufactured by Enzo Diagnostics). After fragmenting the cRNA, hybridization is performed using a DNA microarray (trade name "Gene Chip Mouse Expression Array 430A" (manufactured by Affymetrix)) and a "hybridization oven" (trade name, manufactured by Affymetrix) to carry out R-pico. The reaction with erythrine-streptoavidine and washing were performed by a "Fluidics station" (trade name, manufactured by Affymetrix), and then the fluorescence intensity was measured by a "Gene Array Scanner" (trade name, manufactured by Affymetrix) to analyze the related gene expression amount. Was performed. In addition, the detection sensitivity of the DNA microarray is 1: 100,000, which is measured by adding and detecting a transcription product obtained from a mouse cDNA clone derived from a mouse total RNA sample. 22,690 genes were detected for the mouse skin-derived total RNA used in this test, and used for the analysis of gene expression increase and decrease. Among them, tyrosinase was encoded by Probe ID: 1448821_at, and the ratio of gene expression intensity was determined from the fluorescence intensity.
시험군과 대조군의 조합은 이하와 같다.The combination of test group and control group is as follows.
시험군: 0.1% 헬리피론 A 함유 MF-1식 10주간 사육(16주령)Test group: Breeding for 10 weeks of MF-1 containing 0.1% Helicipron A (16 weeks of age)
대조군: MF-1식 10주간(16주령)Control group: MF-1
또한, 표 4 중의 「Accession No.」는 각 유전자의 GenBank(NCBI의 핵산 서열 데이터베이스)에 있어서의 식별번호이고, Probe Set ID는 Affymetrix사제 Gene Chip Expression Array 고유의 식별번호이다.In Table 4, "Accession No." is an identification number in GenBank (nucleic acid sequence database of NCBI) of each gene, and a probe set ID is an identification number unique to Gene Chip Expression Array manufactured by Affymetrix.
이 표 4로부터, 마우스 피부조직에 있어서 티로시나아제의 유전자 발현이 헬리피론 A에 의해 억제되고, 티로시나아제의 피부에 있어서 과잉 발현이 억제되어, 티로시나아제에 의한 멜라닌 형성이 헬리피론 A에 의해 억제되는 것을 알 수 있었다.From Table 4, gene expression of tyrosinase is inhibited by helipyron A in mouse skin tissues, overexpression is inhibited in the skin of tyrosinase, and melanin formation by tyrosinase is inhibited by It can be seen that it is suppressed by.
[피부조직 중 증식세포 핵 항원(Proliferation Cell Nuclear Antigen)의 측정][Measurement of Proliferation Cell Nuclear Antigen in Skin Tissue]
증식세포 핵 항원(Proliferation Cell Nuclear Antigen, PCNA)은 면역조직화학적 수법을 사용하여 측정하였다.Proliferation Cell Nuclear Antigen (PCNA) was measured using immunohistochemical techniques.
파라핀 포매를 끝낸 마우스 피부조직에 대해서, 탈 파라핀 처리를 정법(定法)에 따라, 항원 부활화는 0.01 M 구연산 완충액(pH 6.0) 중에서 마이크로파 처리 5분을 실시하였다. 실온까지 냉각 후, 상온하 0.3% 과산화수소 함유 메탄올에서 20분 반응시켜 내인성 퍼옥시다아제를 저해하였다. 수세, 10 mM PBS(-) 세정 후, 토끼 혈청 75배 10 mM PBS(-) 희석 용액에서 5분간 마이크로파 처리를 실시하여 블로킹하고, 블로킹 종료 후에 토끼 혈청을 떨어뜨려 1차 항체(PC10: DAKO제)를 500배 희석한 것을 첨가하여 20분간 마이크로파 처리에 의해 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, 비오틴화 2차 항체(비오틴화 토끼 면역 글로불린 M; DAKO제)를 300배 희석한 것을 첨가하여 5분간 마이크로파 처리로 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, ABC 시약(ABC-HRP; Vectastain제)을 첨가하여 5분간 마이크로파 처리에 의해 반응시켰다. 발색 시약으로서 DAB(3,3-디아미노벤지딘테트라히드로 클로라이드: DAKO제)를 사용하여 3분 30초 상온하에서 반응시켰다. 수세 후, 공지의 방법을 토대로 하여 탈수, 봉입 처리를 행하였다. 현미경하에서 피부조직의 염색 상황을 관찰하였다. 자외선 조사 10주간의 검체는 PCNA의 증가에 의해, 표피세포 중 주로 세포핵이 발색되므로, Adobe Photoshop을 사용하여 화상을 읽어들여, 화상 중 일정 면적 중의 염색 개소를 NIH Imaging으로 수치화하였다.The mouse skin tissues after paraffin embedding were deparaffinized, and the antigen-activation was carried out for 5 minutes with microwave treatment in 0.01 M citric acid buffer (pH 6.0). After cooling to room temperature, the mixture was reacted for 20 minutes in methanol containing 0.3% hydrogen peroxide at room temperature to inhibit endogenous peroxidase. After washing with water and washing with 10 mM PBS (-), blocking was performed by microwave treatment in a rabbit serum 75-fold 10 mM PBS (-) diluted solution for 5 minutes, and after the blocking was completed, the serum of the rabbit was dropped and the primary antibody (PC10: manufactured by DAKO) ) Was diluted 500-fold and the antibody was reacted by microwave treatment for 20 minutes. After washing twice with 10 mM PBS (-), the diluted biotinylated secondary antibody (Biotinylated Rabbit Immunoglobulin M; manufactured by DAKO) was added, and the antibody was reacted by microwave treatment for 5 minutes. It was washed twice with 10 mM PBS (-), and reacted by microwave treatment for 5 minutes by adding ABC reagent (ABC-HRP; manufactured by Vectastain). The reaction was carried out at room temperature for 3
각 군의 수치에 대해서 평균값±S.D.를 구하였다. 두 군간의 유의차(有意差) 검정은 UV(-)군을 기준값 1로 하여 각 군의 평균값을 보정 후, student's t-test(유의 수준 p<0.05)로 실시하였다. 측정한 샘플을 표 5에 나타내고, 결과를 도 10에 나타내었다.The mean value ± S.D. was obtained for the numerical values of each group. The significant difference test between the two groups was performed with the student's t-test (significance level p <0.05) after the mean value of each group was adjusted with the UV (-) group as the reference value of 1. The measured sample is shown in Table 5, and the result is shown in FIG.
헬리피론 A를 섭취한 마우스의 피부조직에 있어서 PCNA는 증가하지 않았다. PCNA는 DNA의 산화나 절단, 및 증식성 피부질환으로서 알려져 있는 건선(乾癬)의 바이오 마커로서 발현 상승이 알려져 있어, 본 시험에 있어서 마우스 피부로의 자외선 조사로 발현 상승하는 PCNA가 헬리피론 A 섭식의 DNA의 산화방지작용, 자외선 장애의 완화작용에 의해 정상 레벨로 되돌아왔다.There was no increase in PCNA in the skin tissue of mice fed helipyrone A. PCNA is known as a biomarker of psoriasis known as oxidation and cleavage of DNA and proliferative skin disease, and the expression of PCNA that is elevated by UV irradiation to the mouse skin in this test is fed Hhelipyron A. It returned to normal level by antioxidant activity of DNA and alleviation of ultraviolet ray disorder.
[피부조직 중 로리크린의 측정][Measurement of LoriClean in Skin Tissue]
로리크린은 면역조직화학적 수법을 사용하여 측정하였다.Loriclean was measured using immunohistochemical techniques.
파라핀 포매를 끝낸 마우스 피부조직에 대해서, 탈 파라핀 처리를 정법에 따라, 항원 부활화는 0.01 M 구연산 완충액(pH 6.0) 중에서 5분간 마이크로파 처리를 실시하였다. 실온까지 냉각 후, 상온하 0.3% 과산화수소 함유 메탄올에서 20분 반응시켜 내인성 퍼옥시다아제를 저해하였다. 수세, 10 mM PBS(-) 세정 후, 염소 혈청 75배 10 mM PBS(-) 희석 용액에서 5분간 마이크로파 처리를 실시하여 블로킹하고, 블로킹 종료 후에 염소 혈청을 떨어뜨려 1차 항체(Loricrin Polyclonal Antibody, Purified: Sigma제)를 500배 희석한 것을 첨가하여 20분간 마이크로파 처리에 의해 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, 비오틴화 2차 항체(비오틴화 염소 면역 글로불린 M; DAKO제)를 300배 희석한 것을 첨가하여 5분간 마이크로파 처리로 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, ABC 시약(ABC-HRP; Vectastain제)을 첨가하여 5분간 마이크로파 처리에 의해 반응시켰다. 발색 시약으로서 DAB(3,3-디아미노벤지딘테트라히드로 클로라이드: DAKO제)를 사용하여 4분 30초 상온하에서 반응시켰다. 그 후, 헤마톡실린으로 세포핵과 조직 전체를 염색 처리하고, 수세 후, 공지의 방법을 토대로 하여 탈수, 봉입 처리를 행하였다. 현미경하에서 피부조직의 염색 상황을 관찰하였다. 자외선 조사 10주간의 검체는 로리크린의 증가에 의해, 표피세포 중 주로 세포핵이 발색된다. Adobe Photoshop을 사용하여 화상을 읽어들여, 화상 중 일정 면적 중의 염색 개소를 NIH Imaging으로 수치화하였다. 측정한 샘플을 표 6에 나타내고, 결과를 도 11에 나타내었다.The mouse skin tissues after paraffin embedding were subjected to deparaffin treatment according to the conventional method, and the antigen activation was subjected to microwave treatment for 5 minutes in 0.01 M citric acid buffer (pH 6.0). After cooling to room temperature, the mixture was reacted for 20 minutes in methanol containing 0.3% hydrogen peroxide at room temperature to inhibit endogenous peroxidase. After washing with water and washing with 10 mM PBS (-), blocking was performed by microwave treatment in a 75
각 군의 수치에 대해서 평균값±S.D.를 구하였다. 두 군간의 유의차 검정은 UV(-)군을 기준값 1로 하여 각 군의 평균값을 보정 후, student's t-test(유의 수준 p<0.05)로 실시하였다. The mean value ± S.D. was obtained for the numerical values of each group. The significant difference test between the two groups was carried out by the student's t-test (significance level p <0.05) after the mean value of each group was adjusted with the UV (-) group as
헬리피론 A를 섭취한 마우스의 피부조직에 있어서 로리크린은 증가하지 않았다. 로리크린은 피부의 종말분화의 마커로서 알려져 있고, 헬리피론 A 섭취에 의해 피부의 노화현상이 억제되어, 정상적인 피부의 분화상태를 유지하는 작용이 인정되었다.Lolliclean was not increased in the skin tissue of mice fed Helipyron A. LoriClean is known as a marker of the terminal differentiation of skin, and the action of maintaining normal skin differentiation is recognized by suppressing aging of the skin by ingestion of helipyrone A.
[피부조직 중 케라틴 1의 측정][Measurement of
케라틴 1은 면역조직화학적 수법을 사용하여 측정하였다.
파라핀 포매를 끝낸 마우스 피부조직에 대해서, 탈 파라핀 처리를 정법에 따라, 항원 부활화는 0.01 M 구연산 완충액(pH 6.0) 중에서 5분간 마이크로파 처리를 실시하였다. 실온까지 냉각 후, 상온하 0.3% 과산화수소 함유 메탄올에서 20분 반응시켜 내인성 퍼옥시다아제를 저해하였다. 수세, 10 mM PBS(-) 세정 후, 염소 혈청 75배 10 mM PBS(-) 희석 용액에서 5분간 마이크로파 처리를 실시하여 블로킹하고, 블로킹 종료 후에 염소 혈청을 떨어뜨려 1차 항체(Mouse Keratin 1(AF109) Polyclonal Antibody, Purified: COVANCE제)를 500배 희석한 것을 첨가하여 20분간 마이크로파 처리에 의해 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, 비오틴화 2차 항체(비오틴화 염소 면역 글로불린 M; DAKO제)를 300배 희석한 것을 첨가하여 5분간 마이크로파 처리로 항체를 반응시켰다. 10 mM PBS(-)로 2회 세정하고, ABC 시약(ABC-HRP; Vectastain제)을 첨가하여 5분간 마이크로파 처리에 의해 반응시켰다. 발색 시약으로서 DAB(3,3-디아미노벤지딘테트라히드로 클로라이드: DAKO제)를 사용하여 3분 30초 상온하에서 반응시켰다. 그 후, 헤마톡실린으로 세포핵과 조직 전체를 염색 처리하고, 수세 후, 공지의 방법을 토대로 하여 탈수, 봉입 처리를 행하였다. 현미경하에서 피부조직의 염색 상황을 관찰하였다. 자외선 조사 10주간의 검체는 케라틴 1의 증가에 의해, 표피세포 중 주로 세포핵이 발색된다. Adobe Photoshop을 사용하여 화상을 읽어들여, 화상 중 일정 면적 중의 염색 개소를 NIH Imaging으로 수치화하였다. 측정한 샘플을 표 7에 나타내고, 결과를 도 12에 나타내었다.The mouse skin tissues after paraffin embedding were subjected to deparaffin treatment according to the conventional method, and the antigen activation was subjected to microwave treatment for 5 minutes in 0.01 M citric acid buffer (pH 6.0). After cooling to room temperature, the mixture was reacted for 20 minutes in methanol containing 0.3% hydrogen peroxide at room temperature to inhibit endogenous peroxidase. After washing with water and washing with 10 mM PBS (-), blocking was performed by microwave treatment in a 75
각 군의 수치에 대해서 평균값±S.D.를 구하였다. 두 군간의 유의차 검정은 UV(-)군을 기준값 1로 하여 각 군의 평균값을 보정 후, student's t-test(유의 수준 p<0.05)로 실시하였다. The mean value ± S.D. was obtained for the numerical values of each group. The significant difference test between the two groups was carried out by the student's t-test (significance level p <0.05) after the mean value of each group was adjusted with the UV (-) group as
헬리피론 A를 섭취한 마우스의 피부조직에 있어서 케라틴 1은 증가하지 않았다. 케라틴 1은 피부의 종말분화의 마커로서 알려져 있고, 헬리피론 A 섭취에 의해 피부의 노화현상이 억제되어, 정상적인 피부의 분화상태를 유지하는 작용이 인정되었다.There was no increase in
처방예를 이하에 나타낸다.A prescription example is shown below.
[처방예 1 캡슐제][
하기 성분을 혼합하고, 젤라틴 및 글리세린을 혼합한 캡슐 기제(基劑) 중에 충전하여, 연질캡슐을 얻었다.The following components were mixed and filled in a capsule base mixed with gelatin and glycerin to obtain a soft capsule.
[처방예 2 정제][
하기 성분을 혼합, 타정(打錠)하여 정제를 얻었다.The following components were mixed and tableted to obtain tablets.
[처방예 3 정제][
하기 성분을 혼합, 타정하여 정제를 얻었다.The following components were mixed and compressed to obtain a tablet.
[처방예 4 쥬스][
[처방예 5 크림][
하기 성분 (1)~(10)을 80℃로 가열 용해하여 유상(油相)으로 한다. 성분 (11)~(13)을 70℃로 가열 용해하여 수상(水相)으로 한다. 유상에 수상을 서서히 첨가하여 유화(乳化)하고, 교반하면서 40℃까지 냉각하며, 추가적으로 30℃까지 교반 냉각하여 크림을 얻었다.The following components (1) to (10) are dissolved by heating at 80 ° C to obtain an oil phase. The components (11) to (13) are dissolved by heating at 70 ° C to obtain an aqueous phase. The aqueous phase was gradually added to the oil phase to emulsify, cooled to 40 ° C while stirring, and further cooled to 30 ° C to obtain a cream.
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006120076 | 2006-04-25 | ||
JPJP-P-2006-00120076 | 2006-04-25 | ||
PCT/JP2007/058643 WO2007125832A1 (en) | 2006-04-25 | 2007-04-20 | Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone a |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080110742A KR20080110742A (en) | 2008-12-19 |
KR101347442B1 true KR101347442B1 (en) | 2014-01-02 |
Family
ID=38655358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087021465A KR101347442B1 (en) | 2006-04-25 | 2007-04-20 | Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone A |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP5266046B2 (en) |
KR (1) | KR101347442B1 (en) |
CN (2) | CN101389327A (en) |
HK (1) | HK1171661A1 (en) |
TW (1) | TWI383793B (en) |
WO (1) | WO2007125832A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010054149A1 (en) | 2010-12-10 | 2012-06-14 | Merck Patent Gmbh | 2-pyrones |
JP5770576B2 (en) * | 2011-09-13 | 2015-08-26 | 株式会社ファンケル | Adiponectin production promoter containing helipyrone A as an active ingredient |
JP6054102B2 (en) * | 2012-08-31 | 2016-12-27 | 株式会社ファンケル | Nitric oxide production promoter or inducer |
WO2015012194A1 (en) * | 2013-07-22 | 2015-01-29 | 学校法人麻布獣医学園 | Male function-improving effect of helipyrone a |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001322932A (en) | 2000-05-16 | 2001-11-20 | Pola Chem Ind Inc | Active oxygen scavenger and active oxygen scavenging composition containing the same |
JP2003321463A (en) | 2002-04-25 | 2003-11-11 | Noevir Co Ltd | Skin care preparation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2819718B1 (en) * | 2001-01-22 | 2005-02-25 | Codif Internat Sa | COSMETIC PRODUCT |
JP4373634B2 (en) * | 2001-11-02 | 2009-11-25 | 焼津水産化学工業株式会社 | Nitric oxide scavenger |
JP2005068103A (en) * | 2003-08-27 | 2005-03-17 | We'll Corporation:Kk | Cosmetic for skin |
JP4643208B2 (en) * | 2003-09-10 | 2011-03-02 | 文陽 江口 | Antioxidant, whitening agent, and external preparation for skin containing the same |
JP4669670B2 (en) * | 2004-06-04 | 2011-04-13 | 株式会社ロッテ | Anti-influenza virus agent and influenza infection suppression product obtained by adsorbing, impregnating and adding the same |
JP2006008566A (en) * | 2004-06-24 | 2006-01-12 | Ichimaru Pharcos Co Ltd | Cosmetic agent containing lactic acid bacteria fermentation product of fruit juice as active ingredient and its application |
JP4438706B2 (en) * | 2005-07-05 | 2010-03-24 | 花王株式会社 | Antioxidant, perfume composition and cosmetic composition |
-
2007
- 2007-04-20 KR KR1020087021465A patent/KR101347442B1/en active IP Right Grant
- 2007-04-20 CN CNA2007800065714A patent/CN101389327A/en active Pending
- 2007-04-20 WO PCT/JP2007/058643 patent/WO2007125832A1/en active Application Filing
- 2007-04-20 JP JP2008513175A patent/JP5266046B2/en active Active
- 2007-04-20 TW TW096113903A patent/TWI383793B/en not_active IP Right Cessation
- 2007-04-20 CN CN201210080551.4A patent/CN102626373B/en not_active Expired - Fee Related
-
2009
- 2009-04-21 HK HK12112433.6A patent/HK1171661A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001322932A (en) | 2000-05-16 | 2001-11-20 | Pola Chem Ind Inc | Active oxygen scavenger and active oxygen scavenging composition containing the same |
JP2003321463A (en) | 2002-04-25 | 2003-11-11 | Noevir Co Ltd | Skin care preparation |
Also Published As
Publication number | Publication date |
---|---|
KR20080110742A (en) | 2008-12-19 |
CN102626373B (en) | 2014-08-06 |
JPWO2007125832A1 (en) | 2009-09-10 |
WO2007125832A1 (en) | 2007-11-08 |
CN101389327A (en) | 2009-03-18 |
JP5266046B2 (en) | 2013-08-21 |
TW200810751A (en) | 2008-03-01 |
HK1171661A1 (en) | 2013-04-05 |
TWI383793B (en) | 2013-02-01 |
CN102626373A (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103479538B (en) | The Dermatologic preparation composition of the flower containing Radix Ginseng or the seed extract of Radix Ginseng | |
EP2659004A2 (en) | Modulation of dynein in skin | |
KR101347442B1 (en) | Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone A | |
EP3475258B1 (en) | Novel autophagy activation-inducing compositions for medical and cosmetic uses | |
WO2020201185A1 (en) | Anti-aging cosmetic composition | |
US20120225141A1 (en) | Substance for restoring normal co-expression and interaction between the lox and nrage proteins | |
JP2009167160A (en) | External preparation, hair restorer, nfat signal inhibitor and calcineurin inhibitor | |
CN109789081A (en) | The method of skin lightening compositions comprising TNFRSF14 inhibiting substances and screening TNFRSF14 inhibiting substances | |
KR101837145B1 (en) | Cosmetic Composition for Promoting Skin Turnover Containing Citrus depressa extracts | |
KR20190047374A (en) | Composition for anti-aging comprising cytochalasin d or sag and method for screening anti-aging substances | |
JP6956957B2 (en) | Hair loss inhibitor | |
JP2001048768A (en) | Cosmetic, quasi-drug, drug and food | |
TW202102250A (en) | Fermentation product of black rice extract and preparation and use of the same | |
US11202751B2 (en) | Whitening cosmetic composition comprising Caragana sinica root extract | |
KR101534557B1 (en) | Skin-whitening composition containing Maackiasin thereof as an active ingredient | |
JP5351488B2 (en) | NFAT signal inhibitor and hair restorer, and novel compound having NFAT signal inhibitory and hair growth activity | |
KR101210471B1 (en) | Competitors of microphthalmia transcription factor and the cosmetic composition for skin whitening comprising the same | |
JP7178257B2 (en) | Bioactive composition containing phosphatidylinositol | |
WO2022210296A1 (en) | Oxytocin signal enhancer and oxytocin-induced keratinocyte proliferation-promoting agent | |
CN107875052B (en) | Purple bamboo shoot tea toning lotion and preparation method thereof | |
JP2023032206A (en) | Oxytocin signal enhancer | |
US9920092B1 (en) | Composition having anti-oxidant, anti-aging, and autophagy activities and uses thereof | |
KR100831419B1 (en) | Composition composition comprising ganhuangenin | |
KR101874683B1 (en) | Composition for skin whitening comprising clusterin | |
KR100813639B1 (en) | Composition composition comprising penduletin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20161129 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20181129 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20191202 Year of fee payment: 7 |